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The modern era of genomics has made sequencing a genome nearly routine. 
Genomics has amassed huge amounts of somatic and disease mutation data, as a result, 
the character sequence of the human genome has been extensively studied.  This 
information is having an impact on the standard of care in the clinical sphere, with an 
increasing number of patients and clinicians turning to sequencing data as a determinant 
of treatment regimen.  Knowledge of human protein coding genes and gene expression 
patterns is extensive, though not absolute.  Venturing outside the relatively well-defined 
protein-coding regions of the genome, much is undetermined.  Genome wide association 
studies (GWAS) have identified many genetic polymorphisms in non-coding regions on 
the genome that contribute to disease risk.  Understanding the mechanisms by which a 
non-coding polymorphism can cause a phenotype demands an understanding of the 
physical organization and structure of chromatin in the eukaryotic nucleus. 
Gene expression data from primary gliolbastoma multiforme tumors (GBM) has 
uncovered the existence of four molecular subtypes, which affects prognosis and 
response to treatment. With the goal of gaining an understanding of transcriptional 
 viii 
regulation in brain cancer, we profiled post-translational modifications of histone H3 in 
primary GBM tumors using ChIP-seq, and profiled gene expression in these tumors as 
well. We used a hidden Markov Model approach to abstract common co-occurrences of 
histone modifications into chromatin states.  We were able to identify signatures 
consistent with known chromatin regulatory motifs, such as enhancers, and a bivalent 
state, marked by an active and repressive histone modification.  These states regulated 
expression in a subtype-specific manner, with the proneural subtype showing a protective 
signature, and the mesenchymal and classical subtypes presenting a signature of invasive 
cellular migration and angiogenesis.  The bivalent and enhancer states controlled a gene 
expression signature strongly suggestive of glioma stem cells (GSCs), the cells thought to 
be self-renewing in GBM.  
As part of profiling gene expression in primary GBMs, we performed RNA-
sequencing in primary normal human astrocytes and six GBM-derived commercially 
available cell lines.  We identified widespread differences in expression between tumors 
and cell lines, as well as a gene interaction network that is common to tumors and cell 
lines, dominated by chromatin remodelers and Rho guanine exchange factors.  
Finally, in a pilot study of 400 patients with atrial fibrillation (AF), we identified 
several SNPs associated with probability of success of cardiac ablation, a surgical therapy 
for AF.  We propose that examining the local topology between a SNP of interest and any 
long-range contacts will help identify regulatory regions that allow a non-coding SNP to 
have an effect on gene expression, and thus phenotype. 
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Chapter 1: Introduction  
Since the first complete sequence of the human genome in 2003, sequence 
variation (and its relationship to phenotype) has been the focus of many genotyping and 
whole genome sequencing studies [1].  Indeed, sequence variation controls a large 
proportion of genetic events that can result in phenotypic changes.  While the relationship 
between coding regions and phenotype is generally well understood, the mechanism of 
how genetic variation in noncoding regions of the genome effects changes in phenotype 
remains obtuse [2].  Given that the adult human body contains over 200 distinct cell 
types, all derived from a single genome, at some level the mechanisms controlling cell 
fate and differentiation must be epigenetic in nature [3].  The effects of genetic 
polymorphisms in noncoding regions require genomic context to elucidate the 
mechanisms at play.  This same genomic context can support efforts to identify the 
epigenetic mechanisms controlling cell fate and differentiation. 
Projects such as ENCODE have amassed a large amount of data defining genome-
wide profiles of DNA binding proteins, such as transcription factors, chromatin 
modifiers, and histone post-translational modifications.  The initial data was derived from 
immortalized cell lines, and this data allowed for identification of patterns in DNA-
binding proteins across multiple cell types [4].  Cell lines, both immortalized and 
primary, allow for identification of genetic pathways and epigenetic processes governing 
development and cell differentiation, including cancer development.  However, cell lines 
are imperfect models for primary tissue [5, 6].  Thus there is a necessity to understand the 
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epigenetic contribution to transcriptional regulation in uncultured tissue. What remains to 
be elucidated is an intimate understanding of how epigenetic signals, such as methylation 
or histone modifications, control cell fate in the adult as well as the developing embryo.   
THE ORGANIZATION OF CHROMATIN WITHIN THE CELL NUCLEUS 
Chromosomal domains; active and repressed compartments 
In any given cell type, which genes are silent or expressed is determined in part 
by structure in the nuclear compartment. Chromosomal painting has revealed that the 
DNA from individual chromosomes tends to cluster together; each chromosome can also 
be divided into active and inactive sections [7].  Inactive regions of the genome were first 
identified by the presence of dark regions near the inner nuclear membrane.  These highly 
compacted regions are termed heterochromatin, and they are transcriptionally silent [8]. 
Undifferentiated cells, such as embryonic stem cells, contain minimal inactive regions of 
this type, with the majority of their chromatin being “open” and accessible to the 
transcriptional machinery [9].   
During the process of cellular differentiation, genes are successively silenced and 
heterochromatin appears at the nuclear periphery; this is also true for induced 
pluripotency [10].  These processes result in two compartments in differentiated cells: an 
“A” compartment, which contains active and open chromatin, and a “B” compartment, 
which contains highly compacted, silent chromatin, and localizes near the nuclear 
periphery (Figure 1.1).  The B compartment is specifically marked by methylation of the 
K9 residue on histone H3 [11], or by methylation of the K27 residue on histone H3 [12].  
These repressive marks promote compaction and specifically restrict access of the 
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transcriptional machinery to the chromatin. The A compartment, in contrast, is 
specifically marked by trimethylation of the K4 residue of histone H3, as well as several 
other “activating” histone modifications, discussed in detail below. 
Looping and topologically-associated domains (TADs) 
Beneath the macro scale localization of chromosomes and compartments in the 
nucleus, there are topologically associated domains, or TADs.  These range from 100 
kilobases (kb) to several megabases (Mb) in size, and represent regions of chromatin that 
tend to interact with one another.  TADs are important in timing the replication of large 
genomes [13], and in determining the functionality of enhancers, regulatory regions that 
drive the expression of distal genes. Potential mechanisms of action for noncoding 
somatic polymorphisms can be reduced in scope by considering what genes, SNPs, and 
regulatory regions are present on the same TAD.  Regions that are linearly far away may 
be topologically close if they’re located within the same TAD [14].  TADs can localize to 
the A or B compartments discussed above, and dimers of the multifunctional insulator 
binding protein CTCF define their boundaries [15].  In this context, CTCF defines large 
loops of active or repressed chromatin, with the elements contained on a given loop being 
more likely to interact, and be in the same compartment. 
The 10nm fiber: “beads on a string” 
When nuclear cell extracts are treated with a high salt solution and examined 
under high magnification, there is an appearance of circular beads on a string of DNA. 
The beads are nucleosomes – a nucleosome is a complex of eight histone proteins, and 
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147bp of DNA is wound around each complex, or octamer [16].  Since DNA is net 
negatively charged, it binds easily to the nucleosome octamers, which are net positively 
charged.   Histone proteins have long terminal tails, which protrude from the nucleosome 
core and can be chemically modified at certain residues [17].  These chemical 
modifications are key to understanding the compartmentalization and function of 
chromatin in detail [18]. 
 
Figure 1.1:  Hierarchical regulation of the eukaryotic genome 
Cartoon model of hierarchical levels of chromatin regulation.  In the eukaryotic cell 
nucleus, chromosomes are organized into domains.  Within these domains, there are “A” 
and “B” compartments.  The lower inset into the nucleus indicates the tightly compacted 
organization of nucleosomes in the “B” compartments. The upper inset into the nucleus 
illustrates the organization of nucleosomes in the “A” compartment.  The A compartment 
is then unwound into the 10nm fiber of nucleosomes connected by linker DNA, and 
finally into naked DNA, with one methylated cytosine indicated in green, as well as a TF 
binding site (for the multifunctional regulatory protein CTCF). 
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THE NUCLEOSOME AS A FUNCTIONAL UNIT OF TRANSCRIPTIONAL REGULATION 
The histone code; histone tails are enriched for PTMs 
Each nucleosome octamer contains four histone peptides (H3, H2A, H2B and H4) 
present in two copies each in a nucleosome octamers.  Each peptide can be extensively 
chemically modified (Figure 1.2).  As in other proteins, lysines, arginines, serines and 
threonines are commonly post-translationally modified.  Because they are the most 
numerous, and also the most studied, the effect of histone H3 modifications on 
transcription and regulation of the genome is best understood at present [19].  These 
modifications can generally be grouped into activating and repressive modifications, 
which are specifically read and written onto the histone tails by a specific broad class of 
enzymes termed “chromatin remodelers.” It should be noted that there are non-canonical 
histone variants, which can switch into nucleosomes in particular cellular contexts, such 
as H2A.X in DNA double strand break repair [20].   
Active chromatin, histone modifications and chromatin modifiers 
There are several modifications to histone H3, which result in a generally active 
state where the DNA underlying the chromatin can be transcribed. Tri-methylation of the 
K4 residue is mediated by the Trithorax complex, which was first discovered in 
Drosophila, and acts in opposition to the Polycomb repressor complex, discussed in the 
next section.  In humans, there are six SET-domain methytransferases that can establish 
H3K4 trimethylation [21, 22]. The K4 residue can also be mono or di-methylated – 
monomethylation is specific for enhancer regions when combined with K27 acetylation 
[23].  Dimethylation specifically marks nucleosomes proximal to transcription factor 
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binding loci [24], and tends to mark cell-type specific genes [25].  Mono- and di-
methylation is catalyzed by the methyltransferase KMT2D that appears to be specific in 
this function [26]. 
Acetylation of histone 3 lysine residues 9 and 27 produces open chromatin. 
Acetylation of the positively charged lysine residue reduces some of the affinity of the 
local DNA for based on charge and produces a more open and accessible conformation of 
the chromatin [27].  K27 acetylation marks promoters and active enhancers [28], and is 
also a predictor of developmental state [29], while K9 acetylation broadly reflects 
promoter regions [30], and selectively marks regulatory elements such as active 
enhancers [31].   
Acetylation is mediated by histone acetylases (HATs), which are frequently 
members of large multiprotein complexes that mediate effects on transcription, such as 
the SAGA complex [32].  Histone deacetylases, or HDACs, reverse lysine acetylation 
and are generally associated with repressive activity [33].  HATs and HDACs can have 
different catalytic specificity depending on their co-interacting proteins, so their 
specificity in vitro may not match their specificity in vivo. 
Repressed chromatin, histone modifications and lysine demethylases 
Silenced chromatin tends to accumulate near the nuclear periphery and is more 
compact than active chromatin. Trimethylation of the K9 or K27 residues of histone H3 
is indicative of silenced chromatin, and this silencing is governed by two distinct 
mechanisms: the Polycomb repressor complex 2 (PRC2) mediates K27 trimethylation, 
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Figure 1.2: The modified nucleosome: common histone PTMs 
Each of the eight histone peptides in a nucleosome octamer can be chemically 
postranslationally modified (PTM) at multiple positions.  The six histone modifications 
illustrated in Chapter 2 are shown on the histone H3 tail in colored text.  Common PTMs 
of other histone tails are displayed in black.  P; phosphorylation, Ub; ubiquitylation, Cit; 
citrullination, Ac; acetylation, Me; methylation, Me1; mono-methylation, Me3; tri-
methylation. 
 
and SUV39H1 catalyzes K9 trimethylation [34].  The PRC2 complex selectively silences 
genes temporally during development [12], and interacts with Polycomb repressor 
complex 1 to prevent DNA methylation of cytosines at these sites.  As DNA methylation 
is generally silencing in nature [35], this is an indicator that polycomb silenced promoters 
are not permanently silent [36, 37].  Heterochromatin is also established during 
development, and is more strongly associated with the nuclear periphery than polycomb 
silencing [8].  The H3K9 methyltransferase KMT1C works in concert with a H3K4 
demethylase (KDM5A) to maintain gene repression, so silencing of genes is not a passive 
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process [38].  When polycomb or heterochromatin silencing is aberrantly removed from 
adult cells, or from tissue specific stem cells, cancer can be the result [39, 40]. 
GENOMIC APPROACHES TO STUDYING CHROMATIN STRUCTURE 
Chromatin-immunoprecipitation followed by sequencing (ChIP-seq) 
Given the massive number of proteins that bind to and modify DNA in some 
fashion, understanding their genome-wide binding patterns is important to understanding 
resulting gene regulatory effects. ChIP-seq allows for identification of the binding 
profiles of chemically modified histones, transcription factors, and components of the 
transcriptional machinery, such as RNA polymerase II (Figure 1.3).  Coupled with RNA 
sequencing, ChIP-seq is a powerful technique for studying how DNA binding proteins 
regulate transcription of the genome [41].   
However, it is a complex technique highly dependent on antibody specificity, and 
specific post-processing quality checking to determine where true binding signal exists 
[42].  When experiments are performed in primary tissues, chromatin degradation can be 
a serious issue that results in a low signal to noise ratio. As such, data derived from ChIP-
seq experiments should be quality checked according to the parameters in the Methods 
section of Chapter 2, and any novel antibodies used for this technique should be validated 
using a successive Western blot and IP-Western to ensure the immunoprecipitation 
process is enriching for the protein or proteins of interest. 
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Figure 1.3: Chromatin immunoprecipitation overview 
Chromatin immunoprecipitation uses formaldehyde to induce covalent cross-linkages 
between DNA and any bound proteins.  The cytoplasm (and any acellular components) is 
removed, and the nuclei are lysed using a gentle detergent and sonication.  From this 
mixture of fragmented chromatin, a specific DNA-protein complex is pulled down using 
an antibody specific to that protein or chemical modification.  The protein:DNA:antibody 
complexes are recovered using agarose beads coated with protein A (a bacterial protein 
that binds the constant region of an antibody).  The bound DNA is purified by reversing 
the formaldehyde cross-linkage, then digesting the protein away using proteinase K.  The 
purified DNA is then sequenced after library preparation.  See the Methods section in 
Chapter 2 for a more detailed protocol. 
Chromatin Conformation Capture and "C" based methods 
 To gain an understanding of the topology of chromatin in the nucleus, Chromatin 
Conformation Capture (3C, [43]) and related “C” techniques identify interactions 
between two loci that are topologically close (but may be linearly distant).  The original  
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Figure 1.4: Circular Chromatin Conformation Capture & sequencing (4C-seq) 
4C-seq identifies long-range interactions between a single locus of interest and all other 
points on the same chromosome.  After cross-linking with formaldehyde, the nucleus is 
lysed, and the chromatin is gently digested using sequential restriction digestion with a 4 
bp restriction site, followed by ligation to create circles of DNA that are topologically 
close and may interact.  Most of the interactions will occur within a Mb of the locus of 
interest, but some will be much further away. The statistical burden to ensure interactions 
occurring over a very long distance are non-random is high, which is why interactions 
between two chromosomes are rarely validated. 
 
technique (3C) could validate a single long-range interaction (e.g. between a distal 
enhancer and promoter pair), while Hi-C interrogates all chromatin interactions across the 
genome on an “all by all” scale [44].  The large size of many mammalian genomes means 
for Hi-C sequencing data to be fine resolution, it must be sequenced very deeply, an 
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expensive prospect.  More tractable is 4C-seq (Figure 1.4, [45]), which looks at all long-
range interactions originating from a single locus.  Since the number of possible 
interactions interrogated is much smaller than for Hi-C, sub-kilobase resolution of long-
range contacts can be established inexpensively. This technique, coupled with ChIP-seq, 
can elucidate plausible mechanisms of action for genetic polymorphisms in noncoding 
regions of the genome by identifying long-range interactions and the different types of 
regulatory complexes or proteins that can be brought into proximity by those interactions.  
Genomic context is important; the chromatin interactions that may dictate an effect in one 
tissue will not necessarily be present in all tissues in the body, and experiments must be 













Chapter 2: Bivalent chromatin domains in glioblastoma reveal a 
subtype-specific signature of glioma stem cells 
 
Glioblastoma multiforme (GBM) can be clustered by gene expression into four 
main subtypes associated with prognosis and survival, but enhancers and other gene 
regulatory elements have not yet been identified in primary tumors. Here, we profiled six 
histone modifications and CTCF binding as well as gene expression in primary gliomas 
and identified chromatin states that define distinct regulatory elements across the tumor 
genome. Enhancers in the mesenchymal and classical tumor subtypes drive gene 
expression associated with cell migration and invasion, while enhancers in proneural 
tumors control genes associated with long-term survival in GBM. We identified for the 
first time in GBM, bivalent domains marked by activating and repressive chromatin 
modifications. Interestingly, the gene interaction network from common (subtype-
independent) bivalent domains was highly enriched for homeobox genes and 
transcription factors, and dominated by the SHH and Wnt signaling pathways. This 
subtype-independent signature of early neural development may be indicative of poised 
de-differentiation capacity in glioblastoma, and could provide potential targets for 
therapy.  
INTRODUCTION 
Glioblastoma multiforme (GBM) is an aggressive primary brain tumor that 
accounts for 52% of all malignant primary brain neoplasias. The median time of survival 
with treatment is 14.6 months; only 5% of diagnosed individuals will survive five years 
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from diagnosis [46, 47]. Given the dismal prognosis of GBM, many studies have focused 
on analysis of whole-genome/exome sequencing and gene expression data from primary 
GBM tumors to identify common gene mutations and expression profiles. These studies 
identified 4 molecular subtypes of GBM – classical, mesenchymal, neural, and proneural. 
These data have been invaluable in identifying genes and gene pathways that drive the 
development of GBM, and the identified subtypes predict some aspects of patient 
prognosis and response to treatment [48]. However, the underlying chromatin context 
that regulates gene expression programs in primary GBM tumors is largely unknown. 
Given that GBM lesions are developmentally plastic, and can change certain aspects of 
their cellular identity, understanding how they vary with regard to their chromatin 
structure will enable identification of key genes and regulatory motifs controlling 
differentiation capacity in GBM.  
While several studies have quantified single histone modifications in GBM-
derived cell lines, none of these studies have been performed in uncultured primary 
tissue, and few have looked at patterns derived from multiple histone modifications in the 
same cell line or tumor [49-53]. These studies established the general trend that 
repressive modifications (particularly polycomb silencing) are globally reduced in GBM, 
and active modifications (such as H3K4me3, H3K9ac, H3K27ac) are generally increased 
across the genome in GBM. This lack of data hinders efforts to conclusively identify and 
characterize the cell types that give rise to glioblastoma tumors.  Indeed, a recent 
chromatin profiling study to identify enhancers revealed cell-type of origin in 
medulloblastoma, but no comparable dataset currently exists for GBM [54]. 
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In this study, we sought to categorize regulatory regions of the genome in primary 
GBM tumors by profiling six post-translational modifications of histone H3, and binding 
of the multifunctional insulator binding protein CTCF, in conjunction with gene 
expression profiling of the same tumors. We used a HMM-based approach [55] and 
identified combinations of chromatin marks that defined distinct regulatory elements 
across the genome (Figure 2.1a). The resulting model encompassed 21 chromatin states 
that identified known regulatory elements such as enhancers and promoters, and 
identified bivalent regions in tumors for the first time. We were able to annotate any state 
in this model with matched expression data, generating a context-dependent view of gene 
expression that also identified regulatory regions that may control gene expression 
indirectly. 
We were able to obtain nine glioblastoma multiforme tumors and two anaplastic 
astrocytoma tumors for this study.  While the sample number was smaller than desired, 
each experiment performed (seven IPs per tumor, plus RNA sequencing) integrates data 
from millions of cells derived from the same homogenized tumor material.  Thus, while 
the data are not as clean as cell lines, or single-cell data, each experiment interrogates the 
genome of millions of cells derived from the same tumor.   
RESULTS 
Gene expression in tumors recapitulates clinically distinct GBM subtypes 
GBM tumors are highly heterogeneous [56], and tumors were homogenized 
before processing, so the data are representative of bulk tumor, as opposed to any specific 
population of cells.  To ensure that the tumors we used for chromatin profiling  
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Figure 2.1: Bulk tumors represent the known molecular subtypes in GBM. 
(a) Overview of our approach. We profiled histone modifications and used ChromHMM 
[55] to produce a model of chromatin states, and associated distinct chromatin states with 
gene expression profiles from the same tumors. 
(b) The panel on the left displays microarray data used by TCGA to establish molecular 
subtypes in GBM [58]. Data were hierarchically clustered on both axes using Spearman’s 
rho. The right hand panel displays RNA sequencing data generated in this study. The 
gene order is the same as on the left, but tumors were hierarchically clustered as above. 
 
represented clinically valid GBM tumors, we analyzed gene expression profiles from the 
same tumors that were used for ChIP-seq. We performed RNA-seq from all primary 
tumors, as well as several commonly used GBM-derived cell lines and two independent 
 16 
lines of primary normal human astrocytes. After alignment, gene expression was 
quantified over protein coding genes using the GENCODE annotation for hg38 [57] 
(Methods).  Using the 836 subtype classifier genes identified by TCGA [58], these data 
were plotted as a heatmap. 
We found the same basic groups and expression patterns as in the TCGA tumors 
despite having many fewer tumors, and using RNA-seq to profile gene expression as 
opposed to the microarray analysis used previously by TCGA (Figure 2.1b). Thus, the 
tumor tumors that we used for chromatin profiling represent authentic and clinically 
relevant GBM subtypes. This comparison allows us to address heterogeneity in tumors as 
well.  As we do not have access to pathology reports derived from the samples used in 
this study, we are unable to know the percentage of tumor (as opposed to stromal, or 
infiltrating) material in each sample.  However, TCGA tumor samples were screened to 
have at least 80% tumor material present [58].  Given that our RNA-seq data cleanly 
replicates the TCGA subtype data, this indicates that the tumors analyzed in this study are 
similarly enriched for tumor material, and are not compared predominantly of stroma or 
infiltrating immune cells.  While we could clearly detect the mesenchymal, classical and 
proneural subtypes, we did not detect any neural subtype tumors. The neural subtype is 
less common than the other 3 subtypes and there is some debate regarding whether the 
neural subtype is a distinct molecular subtype in GBM [48, 59, 60].  
Two meningioma tumors clustered with the classical GBM subtype and were not 
used in subsequent analyses. GBM cell lines differed widely from the tumors in their 
gene expression patterns, and thus are not an accurate model of primary tumor lesions for 
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genome-wide profiling studies. When we clustered all the tumors on the 836 subtyping 
genes identified by TCGA, three groups were evident: tumors, normal human astrocytes, 
and GBM-derived cell lines (Figure 2.2).  
Global profiling of histone modification reveals biologically relevant patterns 
To profile regulatory chromatin states in GBM, we developed a protocol to 
perform ChIP-seq in fresh-frozen primary GBM tumors (Methods) and concurrently 
sequenced the RNA derived from these tumors. We profiled four active histone 
modifications (H3K4me1, H3K4me3, H3K9ac, H3K27ac) and two repressive histone 
modifications (H3K27me3, H3K9me3) as well as the multifunctional insulator binding 
protein CTCF. Transcribed genes such as calmodulin (CALM1) displayed active histone 
modifications (Figure 2.3a), while transcriptionally silent genes such as keratin 72 
(KRT72) showed broad repressive marks (Figure 2.3b). Genome-wide, active or 
repressive marks and CTCF binding clustered together, with tumors showing a given 
mark generally clustering together (Figure 2.3c,d). Thus, the biological state of the 
chromatin rather than tumor identity determined the clustering of datasets, indicating that 
our profiling data was reflective of the underlying chromatin state.  
To systematically identify distinct chromatin states in the tumor genomes, we first 
called ChIP-seq peaks in each tumor, then used ChromHMM [55] to build a 21-state 
model of combinations of histone modifications across the genome (Methods).  To focus 
on epigenetic states in GBM, we used only profiling data from GBM tumors to generate 
the model. Based on known associations of histone marks and CTCF binding with 
regulatory activities, we identified several functionally distinct chromatin states in the  
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 Figure 2.2: Expanded subtyping and clustering data, including GBM-derived cell lines. 
Clustering of RNA-seq data over the 836 TCGA subtyping genes in Figure 2.1 for all 
samples, both tumors and GBM-derived cell lines. Tumors were hierarchically clustered 
using Spearman’s rho, with cuffnorm-derived FPKM values (Methods).  Tumor color 
corresponds to subtype. 
 
tumor genome [3, 28, 61]. There were several promoter and enhancer-like states, 
including an active enhancer state, polycomb and heterochromatin silenced states (Table 
2.1). Interestingly, the 21-state model revealed the existence of a bivalent state marked by 
active H3K4me3 and repressive H3K27me3 modifications. Such bivalent states were first 
identified in embryonic stem cells (ESCs) [62], and have been identified in glioblastoma 
derived cell lines [63, 64] but to our knowledge, this is the first time they have been seen 
to exist in primary GBM tumors. A view of the ChIP-seq signal surrounding a given  
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Figure 2.3: Epigenetic profiles in GBM tumors. 
(a) Active chromatin over the promoter region for calmodulin (CALM1), which is highly 
expressed in the tumor GBM7. Region displayed: chr14:90,391,001-90,427,000 on the 
hg38 assembly. (b) A polycomb-repressed region, marked by H3K27me3, in the same 
tumor as a over the gene KRT72, which encodes a keratin protein. Region displayed: 
chr12:52,580,318-52,607,332 on the hg38 assembly. (c) A clustered correlation heatmap 
of all chromatin profiles generated in this study. Pairwise correlation coefficients across 
the 33,188 genomic loci with measurable signal in at least 15 experiments are shown, 
with clusters of chromatin marks indicated by the text. (d) Heatmap of normalized ChIP-
seq signals in the same genomic loci shown in c. Both genomic loci (vertical) and 
experimental tumors (horizontal) were hierarchically clustered. 
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state median cov 
total 
cov CTCF K9ac K27ac K4me1 K4me3 K9me3 K27me3 class  
1 0.18% 3.33% 1.1% 0.1% 0.2% 0.8% 0.0% 99.4% 0.8% heterochromatin   
2 0.00% 0.43% 4.4% 2.0% 0.0% 11.6% 99.7% 99.2% 0.0% repressed   
3 0.54% 3.56% 2.6% 0.0% 0.0% 0.0% 99.2% 0.0% 0.0% h3k4me3   
4 0.36% 2.09% 0.0% 100.0% 0.0% 0.0% 100.0% 0.1% 0.0% weak promoter   
5 0.05% 0.44% 7.1% 99.3% 0.0% 99.1% 100.0% 0.1% 0.1% weak promoter   
6 0.09% 0.80% 8.7% 99.5% 99.9% 99.3% 99.9% 0.2% 0.7% strong promoter   
7 0.54% 1.80% 0.0% 99.7% 99.9% 0.0% 100.0% 0.2% 0.0% promoter   
8 0.14% 1.31% 4.0% 99.3% 99.0% 0.0% 0.0% 0.1% 0.0% weak enhancer   
9 0.07% 0.66% 4.0% 99.4% 99.2% 99.3% 0.0% 0.1% 0.1% weak enhancer   
10 0.06% 0.58% 4.3% 99.0% 0.0% 99.1% 0.0% 0.1% 0.0% weak enhancer   
11 0.26% 2.90% 1.4% 0.0% 0.0% 98.4% 0.0% 0.8% 0.1% Inact. enhancer   
12 0.07% 0.80% 1.7% 0.0% 99.0% 99.2% 0.0% 8.2% 0.2% enhancer   
13 0.51% 5.17% 1.2% 0.0% 97.9% 0.0% 0.0% 2.1% 0.0% h3k27ac   
14 0.06% 1.41% 3.3% 0.0% 99.4% 7.1% 99.7% 31.3% 0.0% weak promoter   
15 0.04% 0.56% 4.0% 0.0% 30.3% 99.1% 99.6% 0.1% 0.0% weak enhancer   
16 0.09% 0.85% 5.8% 37.3% 19.0% 10.7% 84.6% 25.9% 99.4% bivalent   
17 0.36% 4.76% 0.7% 0.0% 0.0% 0.2% 0.0% 4.1% 98.1% polycomb   
18 95.15% 98.97% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% no signal   
19 0.47% 4.17% 3.9% 98.1% 0.0% 0.0% 0.0% 0.0% 0.0% h3k9ac   
20 0.08% 0.42% 100.0% 97.0% 63.3% 0.0% 99.3% 0.3% 0.2% wk prmt + ctcf   
21 0.24% 1.31% 99.8% 0.5% 0.6% 0.3% 2.7% 0.1% 0.0% ctcf binding   
Table 2.1: A 21-state model of chromatin states in the GBM genome.   
The above table represents the output of ChromHMM for a model with 21 states.  The 
“median cov” indicates the median percentage of the hg38 genome covered by that state 
for any tumor, while “total cov” indicates the maximum coverage of that state over all 
tumors. Columns 4-10 indicate the proportion of a given state marked by each chromatin 
mark. 
 
chromatin state in a tumor showed that globally, the identified states faithfully reflected 
the underlying combinations of histone marks (Figure 2.4). At individual loci, the 
identified states captured the appropriate combination of marks corresponding to different 
types of functional elements such as promoters and enhancers, or silenced 
heterochromatin regions (Figure 2.5).  Although expression across the states was 
variable, any state with a repressive mark was associated with a statistically significant 
reduction in expression compared with other states (Figure 2.6a). 
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Figure 2.4: Epigenetic signal surrounding four chromatin states in GBM4. 
The above image represents the sequencing signal (aligned reads) from four histone 
modifications as well as RNA sequencing surrounding four chromatin states.  Each 
square is 20kb wide – 10kb upstream and 10kb downstream of the center of the 
chromatin state locus.  Several thousand individual regions were surveyed for each 
chromatin state, and the y-axis sort order is the same across each row.  The promoter state 
is sorted by the H3K4me3 signal, the enhancer state is sorted by the H3K4me1 signal, 
and the bivalent and polycomb states are sorted by the H3K27me3 signal.  The aggregate 
number of reads across the center 2kb determines the sort order for each state. 
 
We used whole genome bisulfite sequencing data from TCGA GBM tumors to examine 
DNA methylation levels corresponding to each state. The polycomb and heterochromatin 
silenced states were highly methylated, reflecting their transcriptional inactivity. 
Interestingly, although the genes nearest enhancers were highly expressed, the enhancers 
themselves were highly methylated (Figure 2.6b).  While methylation is generally 
considered to be silencing [35], WGBS is unable to distinguish between methylation and  
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Figure 2.5: A view of 877 kb on chromosome 1 for the tumor GBM8 
The figure above illustrates 7 ChIP-seq tracks, RNAseq, chromatin states and gene 
annotations. Below, a close-up view of chromatin states showing, from left, a weak 
enhancer, a promoter, and a heterochromatin-silenced region over a lncRNA of unknown 
function. Region displayed on the hg38 assembly: chr1:18,621,857-19,499,690. 
 
5-hydroxymethylation (5hmC) of cytosine residues. Enhancers and gene bodies are 
specifically marked by 5hmC in ES cells [65, 66] and in GBM [67]. Using regions of 
high 5hmC from Johnson et al., [67] our enhancers are enriched for 5hmC compared to 
promoters (t-test; P = 6.212e-07), bivalent regions (P = 4.08e-09), polycomb silenced 
regions (P =1.866e-09),  and are enriched compared to background levels in the genome 
(P = 2.778e-12) (Figure 2.7a). Genes corresponding to bivalent states were not 
expressed, and bivalent loci showed lower levels of methylation than polycomb and 
heterochromatin silenced regions. CTCF binding sites were associated with high levels of 
methylation, consistent with previous reports [68]. 
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Figure 2.6: Expression and methylation across 4 chromatin states. 
(a) Average expression of genes closest to each of the four states displayed in Figure 2.4. 
Normalized FPKM counts across all tumors were derived from cuffnorm (Methods). 
(b) Average methylation across each of the states in Figure 2.4. Fractional methylation 





Figure 2.7: 5hmC signal over enhancers, enhancer distance to genes, average expression 
of enhancer-associated genes by tumor. 
(a) 5-hydroxymethylation data from Johnson et al. [67] over five chromatin states from 
the model, promoter, enhancer, bivalent, polycomb and no signal (state 18, background). 
(b) Boxplots by subtype displaying the data on distance from enhancers to the closest 
proximal gene; the distances displayed are only from enhancers that are not located 
within a gene body.  
(c) Average expression of genes proximal to enhancers in each tumor. FPKM calculated 
as before, and tumors are colored by subtype.  
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GBM enhancers are located predominantly within introns and intergenic regions, 
and contain degenerate STAT/Klf/SP family motifs 
 Table 2.2: Enhancer counts for this dataset 
Active enhancers varied widely in number among tumors, with a median number 
of 3,640 (Table 2.2). Though expression levels for genes associated with enhancers 
varied across tumors, there were no statistically significant changes in expression across 
tumors or subtypes or in the average distance to a gene (Figure 2.7b,c). Generally, 
enhancers localized within or upstream of gene bodies. The vast majority of enhancers in 
any given tumor were located in introns. The genomic distribution of enhancers that we 
identified in GBM tumors [54] and one from enhancers defined in cell lines by ENCODE 
[69] (Figure 2.8a).  
We used MEME-ChIP [70] to identify de novo motifs overrepresented in 
enhancers in each tumor. These motifs were largely degenerate, and bore resemblance to 
motifs for several families of transcription factors, such as a TTYCY short motif, with 
some similarity to KLF and STAT-like binding motifs (Figure 2.9). Other short motifs 
resembled portions of the NFATC2 DNA-binding region, with representation by several 




3640 5658 33 8077 2191 5091 1783 4135 6401 1906 1908 
Inactive 
enhancer           
(State 11) 
11745 25828 1095 40921 9245 12332 17169 3260 14065 5951 9960 
H3K27ac 
peaks 30979 62605 38262 44629 40024 49276 42779 60416 31341 34406 36431 
H3K4me1 
peaks 17437 45473 3324 59145 12890 22190 25253 9375 23910 13420 17183 
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ETS-family transcription factors (EHF, ETV2). Several less degenerate 6-8 mers motifs 
strongly resembled primary and secondary binding sites for the AP2 transcription factor  
family, as well as TCF3, ASCL2 and TCF5. The observed motifs indicate that enhancers 
are enriched for binding of transcription factors controlling cellular proliferation and 
immune response. 
Enhancers are subtype-specific and control genes involved in cell-cell contacts 
The enhancer state in our model is defined by co-localization of H3K27ac and 
H3K4me1 (Figure 2.4, Table 2.2).   This is a chromatin-based definition of enhancers, as 
opposed to the more classical definition of regions that can drive lacZ or gal4 expression 
in an animal model.  Properly, these regions are putative enhancers, as they are untested 
for driving expression of a reporter gene in an animal model, though analysis of matched 
expression data indicates genes affiliated with an enhancer do have higher expression 
than genes associated with a promoter alone (Figure 2.6). 
Some transcriptional activity originated from these regions, but in a less defined 
manner than that from promoter regions (Figure 2.4). 1,817 enhancers, which covered 
1,227 genes, were present in at least 3 out of 11 tumors and we defined this set as our 
“common enhancers”. 307 of these genes were strongly enriched for pathways that 
mediate cell-cell interactions such as cell adhesion and cell-cell adherens junctions 
(Figure 2.8b). These enrichments were driven by many groups of genes, such as laminins 
(LAMA5, LAMB3), cadherins, (CDH1, CDH4), integrins (ITGA11, ITGB5), catenins 
(CTNNA1, CTNND1, CTNND2), cell adhesion molecules (CADM1, HEPACAM, 
NCAM1, NRCAM), myosins (MYO1E, MYH9, MYH10) and actinins (ACTN1, ACTN4). 
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Figure 2.8: GBM enhancers regulate gene expression in a cell-type specific manner.  
(a) The distribution of enhancers identified in this study across defined elements in the 
genome (Methods), compared with two external enhancer datasets: Common and 
differentially regulated medulloblastoma enhancers [54] and Dragon DB enhancers 
defined by ENCODE in cell lines [69]. (b) Functional enrichment for genes associated 
with enhancers in at least 3 tumors. Benjamini adjusted P-values provided by DAVID 
[71] are shown to the side of each bar, with the shading proportional to the significance. 
(c) Heatmap of gene expression from the 307 enhancer associated genes with a functional 
annotation in a. (d) A 140 kb genome browser view of the region surrounding the gene 
PODXL. This enhancer is subtype-specific, and is much stronger in the MES/CL tumors 
(indicated by purple bars, with the enhancer region in MES/CL tumors outlined by a red 






Figure 2.9: Sequence motifs in enhancers. 
De-novo motifs identified by MEME-ChIP for each tumor. The first column indicates the 
tumor, followed by the number of enhancer regions that were analyzed. Within each 
motif entry, we list the P-value of the motif identified, then the number of occurrences of 
that motif, on the lower left and lower right of each panel, respectively. The upper right 
hand corner indicates the most similar motif identified by TOMTOM. The first four 
motifs identified by MEME are listed first, and the fifth column lists the most significant 
motif identified by DREME, a program focused on identifying shorter motifs de novo. 
DREME and TOMTOM are programs in the MEME suite [70], which was used for this 
analysis. 
 
These 307 genes with a DAVID annotation from Figure 2.8b were split between 
proneural (PN) and mesenchymal/classical (MES/CL) tumors, with genes expressed in 
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PN tumors being minimally expressed in the MES/CL tumors and vice versa (Figure 
2.8c). Of these 307 genes, 33 were on the TCGA list of subtype genes [48]. This includes 
five genes significantly upregulated in the proneural tumors (EPHB1, MAPT, NCAM1, 
KIF21B, STMN1), and two genes that are significantly up in the MES/CL tumors (EGFR, 
OSBPL3), in addition to 26 genes that are not statistically different across the two sets. In 
total, we identified 274 novel genes associated with GBM that are controlled by an 
enhancer in at least 3 tumors. The subtype specificity of enhancers was often visually 
evident, as with the gene PODXL, which showed strong enhancer signals and expression 
in the MES/CL tumors, but much weaker enhancer signals and expression in PN tumors 
(Figure 2.8d). 
Bivalent regions are enriched for hedgehog signaling and developmental genes 
Table 2.3: Bivalent domain counts for this dataset  
The model identified a bivalent state (state 16, Table 2.3) predominantly defined 
by co-localization of H3K4me3 and H3K27me3 (Figure 2.4). Transcription from this 
state was slightly higher than a polycomb silenced state, but lower than genes near active 
promoters or enhancers (Figure 2.4, Figure 2.6). There were 2,027 frequently bivalent 
regions that were present in at least 5 tumors, and these regions covered 1,510 distinct 
 GBM1 GBM2 GBM3 GBM4 GBM5 GBM6 GBM7 GBM8 GBM9 AA1 AA2 
Bivalent 
(State 16) 1719 1367 824 2638 1661 2202 4532 3615 10565 5514 1789 
Polycomb 
(State 17) 4472 6672 19861 10841 7635 6791 43376 17833 43885 22159 4348 
H3K4me3 
peaks 54308 29580 38949 45845 23378 32594 29330 32866 41956 34173 33639 
H3K27me3 
peaks 4947 7975 20709 12068 8553 7538 48672 19630 48136 25331 5129 
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genes (Methods). 840 of these genes showed strong enrichment for pattern specification, 
regionalization, embryonic development and transcription factor activity (Figure 2.10a) 
and clustered with a PN versus MES/CL division in gene expression, similar to 
enhancers. Frequently bivalent regions were divided in expression by subtype and fell 
into 2 groups: Group 1 contained genes that were expressed in MES/CL tumors and were 
often bivalent in PN tumors, and Group 2 showed largely the reciprocal pattern (Figure 
2.10b, Figure 2.11). For example, Group 1 contained many genes in the HOXB locus 
that were bivalent in PN tumors but expressed in MES/CL tumors (Figure 2.10c). 
To identify regions that were bivalent in a subtype independent manner in GBM, 
we examined bivalent regions common to at least 8 out of 11 tumors, and identified 467 
regions, which covered 381 unique genes. 68 of these 381 genes (17.8%) were homeobox 
genes, a highly significant enrichment given that only 1.25% of all genes are homeobox 
genes (P < 2.2 e-16, Fisher’s Exact Test). Moreover, there were 127 transcription factors 
(33.3%) among the 381 commonly bivalent genes, an equally significant enrichment (P < 
2.2 e-16, Fisher’s Exact Test) compared to the 10% of all genes that are transcription 
factors. The occurrence of homeobox genes and transcription factors is thus likely to 
represent a functional attribute of bivalent chromatin domains in GBM. The bivalent 
regions were characterized by punctate H3K4me3 marks, with H3K27me3 more broadly 
distributed across the region (Figure 2.10c). The commonly bivalent genes were highly 
interconnected, with 192 of the genes connected through StringDb [72]. 30 genes were 
not connected to the main network, so the primary network comprises 162 nodes. Using 
HumanNet, 176 of the nodes were connected (AUC = 0.612; P  = 1.54e-12) [73]. The  
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Figure 2.10: Bivalent regions underlie Wnt and SHH signaling in GBM. 
(a) Functional enrichment for genes associated with bivalent domains in at least 5 tumors. 
FDR adjusted P-values provided by DAVID are shown above each column, with the 
shading proportional to the significance. (b) Heatmap of gene expression from the 840 
genes with DAVID annotations in a, demonstrating clustering of PN and MES/CL 
tumors with regard to gene expression. The genes are sorted based on the ratio between 
average FPKM values across PN and MES/CL groups. (c) A genome browser view of a 
90 kb region on chromosome 17, encompassing the HOXB cluster of genes. From top to 
bottom, tracks show chromatin states, genes, RNA-seq, H3K4me3 binding, and 
H3K27me3 binding. Proneural tumors (green bars) are bivalent, while 4 out of 6 
MES/CL tumors (purple bars) show expression over this region. The hg38 coordinates of 




Figure 2.11 Expression and chromatin signal for bivalent domains and associated genes. 
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Figure 2.11 Expression and chromatin signal for bivalent domains and associated genes. 
 
(a) Gene expression data in FPKM, separated by subtype and by bivalent group as shown in 
Figure 2.10b; Group 1 genes are expressed in MES/CL tumors and bivalent in PN tumors, 
Group 2 indicates genes that are expressed in PN tumors and bivalent in MES/CL tumors.  
(b) As in a, but data have been broken out by tumor.  
(c) Chromatin signal data for H3K4me3 and H3K27me3, separated by subtype and by 
bivalent group as shown in Figure 2.10b.  


























Figure 2.12: Interconnectivity between genes identified as bivalent in at least 8 tumors.   
StringDb [72] was used to identify edges between nodes, and Cytoscape [74] was used to 
make the resulting plot. The number of connected edges scales with node size. The seven 
most common functional gene classes are colored, with a legend at the bottom of the 
panel; TF = transcription factor, RTK = receptor tyrosine kinase. 
 
resulting network is dominated by SHH and IHH, with WNT1, GATA-family 
transcription factors (GATA2, GATA3, GATA4, GATA6), and the growth factor FGF10 
forming additional hubs (Figure 2.12). The presence of bivalent chromatin domains in 
cancer may indicate de-differentiation towards a more stem-cell like phenotype. 
DISCUSSION 
Although gene expression profiling of primary tumors suggests 4 molecular 
subtypes – classical, mesenchymal, neural and proneural – detailed phenotypic and 
molecular characterization of glioma stem cells (GSCs), which are thought to be the 
tumor initiating cells in glioblastoma, reveal two distinct subtypes of GSCs, 
corresponding to the mesenchymal and proneural types [75]. Strikingly, the genes 
targeted by the enhancers and bivalent chromatin states that we identified in primary 
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tumors also separate them into two groups corresponding to the GSC-based classification 
of GBM. Moreover, genes targeted by enhancers appear to regulate pathways that are 
differentially active in the two GSC subtypes.  
Many enhancer-associated genes that were significantly upregulated in MES/CL 
tumors promote cellular invasion and angiogenesis, a hallmark of mesenchymal GSCs 
[76, 77]. For example, PODXL (Podocalyxin-like) promotes cell migration, and its 
overexpression in GSCs is associated with a poor outcome [78]; MMP11 (Matrix 
metalloprotease 11) cleaves the extracellular matrix, and promotes tumorigenesis and 
cellular invasion [79]; S100A16 (a Ca++ binding protein) promotes the epithelial-to-
mesenchymal transition (EMT) in breast cancer [80]; the protein kinase FAM20C is a 
marker of mesenchymal GSCs and promotes proliferation in triple-negative breast cancer 
[81]; LMO2 (LIM Domain Only 2) promotes erythropoiesis and angiogenesis [82, 83], 
and is also a marker of GSCs [76, 77].  Integrin alpha 11 (ITGA11) is highly expressed in 
invasive triple negative breast cancer cells [84], and is involved in the tumorigenicity of 
non-small cell lung cancer [85]. 
Conversely, many enhancer-associated genes significantly upregulated in PN 
tumors were associated with increased survival. The AKT3 isoform of AKT is inversely 
correlated with malignancy in GBM [86, 87], while dynamin-1 (DNM1) is associated 
with long-term survival in GBM [88]. Tenascin R (TNR) promotes the assembly of 
perineuronal nets, which stabilize synapses in the adult brain [89, 90]; in embryonic stem 
cells, it promotes differentiation into the neuronal lineage [91]. Neural cell adhesion 
molecule 1 (NCAM1) is involved in neuron-neuron interactions in the brain, and when 
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repressed, the Wnt/β-catenin pathway is activated and cellular invasion increases in vitro 
[92]. KCNIP3 interacts with potassium voltage gated ion channels, and is a negative 
regulator of N-cadherin processing [93], which may indicate an anti-cancer effect, given 
that N-cadherin expression is important for cancer cell metastasis [94].  
The differentially expressed genes MICAL2, STMN1 and MYH10 are indicative of 
cellular proliferation and cytoskeletal destabilization in PN tumors. MICAL2 destabilizes 
F-actin in both neural and non-neural cells [95] and is associated with EMT and actively 
metastasizing cancer cells; when knocked down in vitro, this effect is abrogated [96]. 
Stathmin-1 (STMN1) destabilizes microtubules, and its expression is increased in 
infiltrative astrocytomas [97], when STMN1 is inhibited, cell proliferation is reduced, and 
cell cycle arrest is observed in vitro [98]. The unconventional non-muscle myosin 
MYH10 is upregulated in PN tumors; unconventional myosins play a large role in control 
of cytoskeletal remodeling in support of lamellipodia spreading [99], as well as collagen 
synthesis [100]. Additionally, MYH10 is important for moving the nucleus of a cell 
through tight spaces during migration to generate force [101]; this process is an important 
aspect of glioma invasion [102].  
Many genes adjacent to frequently bivalent regions could be placed into two 
groups showing the same reciprocal relationship in expression between MES/CL and PN 
tumors as observed with enhancer-associated genes (Figure 2.8c, Figure 2.10b, Figure 
2.11). Thus, many Group 1 genes active in MES/CL tumors, such as COL6A2, SMOC2, 
ITGB2, FOXC2 and HOXB3 have been associated with angiogenesis, cellular migration 
and invasive growth. In primary and metastatic brain tumors, COL6A2 expression is 
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associated with angiogenesis [103]. SMOC2 is associated with endothelial cell 
proliferation and angiogenesis [104] and a Wnt-associated signature of stemness in 
intestinal crypt cells [105], which is required for progression of colon cancer [106]. 
ITGB2 is involved in cellular migration, particularly of leukocytes along endothelial cell 
walls, which has implications for metastasis [107]; when mutated, it is associated with 
increased risk of glioma [108]. The Wnt signaling pathway transcription factor LEF1 
regulates stem cell renewal in GBM [109], and does this through activation of Wnt 
signaling [110]. The transcriptional activator FOXC2 induces EMT [111, 112], enhances 
cell invasion and proliferation in GBM [113], and increases angiogenesis in a HUVEC 
model system [114]. The transcription factor HOXB3 promotes invasiveness in prostate 
cancer [115], and when degraded, the cancer stem cell phenotype in ER+ breast cancer is 
inhibited [116].  In MES/CL tumors, the Hh target gene GLI1 is highly expressed, and is 
an indicator of reduced survival in GBM [117]. The high expression of GLI1 in the 
MES/CL group drives high expression of its target gene MDM2, a ubiquitin ligase which 
degrades TP53 [118]. 
Some Group 2 genes active in PN tumors were protective. For example, ICAM5 is 
an intracellular adhesion molecule that regulates interactions between neurons and 
microglia [119, 120], and it is often repressed in colon cancer [121]. Another Group 2 
gene, SLIT2, provides axon guidance in the developing forebrain, and patients with SLIT2 
positive gliomas show better survival [122].  LINGO1 is a negative regulator of 
myelination in oligodendrocytes [123, 124], and when inhibited in NSCs, the neuron 
lineage doesn’t mature [125]; it promotes apoptosis after neural injury by inhibiting 
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WNK3 kinase [126]. 
However, other Group 2 genes highly expressed in PN tumors were strongly 
suggestive of GSCs. Notable among these was OLIG2, a lineage specific transcription 
factor for oligodendrocytes that is required for proliferation of GSCs [127, 128]. OLIG2 
regulates PDGFRA [129], which was also a Group 2 bivalent gene highly expressed in 
PN samples, and its expression is associated with an improved prognosis [130], though 
PDGFRA is also required for gliomagenesis [131].  Fibroblast growth factor 9 (FGF9) is 
a mitogen consistently expressed in human gliomas [132]; in ovarian cancer, FGF9 
expression is associated with activation of the Wnt and Hh signaling pathways [133]. 
Genes marked by bivalent chromatin in 70% of GBM (8/11 tumors) were highly 
interconnected and formed a network dominated by Wnt (WNT1, WNT2B, WNT6), and 
hedgehog (SHH, IHH) signaling, HOX and homeobox genes, and transcription factors. 
This bears strong similarity to signatures of bivalent chromatin both in embryonic stem 
cells, where the opposing active and polycomb repressed marks poise genes for 
developmental expression, as well as in cancer stem cells (CSCs) [62, 134, 135].  WNT5B 
was recently identified as vital for differentiation and cell growth in GSCs [139]. 
Expression of HOX gene loci in GBM is associated with a stem-cell signature of self-
renewal and resistance to chemotherapy [136-138].  The enrichment for bivalent marks 
over HOX gene loci correlates with these findings, and indicates that bulk tumor may 
have some pre-existing activating histone modifications of GSC-relevant loci. However, 
true bivalent loci marked by H3K4me3 and H3K27me3 have not been identified 
previously in primary GBM tumors. Unexpectedly, the bivalent signature associated with 
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GSCs, which comprise a small fraction of the overall tumor, was instead observable in 
the bulk tumor. 
Wnt and Hh signaling regulate EMT, invasion and proliferation in cancers, and 
certain components of these pathways were expressed in the GBM tumors profiled here. 
However, the master regulators IHH, SHH, and WNT1 were nearly always silent, but 
poised for expression. The large number of transcription factors and homeobox genes that 
were commonly bivalent suggests a rapidly deployable program that allows for an Hh 
and Wnt-mediated transcriptional response that may drive the production of multipotent 
stem cells from more differentiated bulk tumor cells. Many of the genes expected to be 
signatures of GSCs specifically were highly expressed in unsorted tumor in a subtype 
specific manner, indicating that the genetic pathways necessary for GSC programming 
are present in any given GBM tumor cell.   The Wnt and Hh pathways offer many 
opportunities for therapeutic intervention [140-142], and it is possible that activating the 
bivalent domains, perhaps using combinations of epigenetic modulators, could expose 
vulnerabilities in tumors that can then be targeted in a subtype specific manner. 
MATERIALS AND METHODS 
Chromatin immunoprecipitation in solid tumors and cell lines 
All patients provided informed consent, and this study was approved by the 
Institutional Review Boards of St. David's Medical Center and of the University of Texas 
at Austin. Tumor tumors were collected during surgical resections as part of the standard 
of care, and only excess tissue that was not used for pathological analysis was used in this 
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study. Tumors were immediately placed in a cryotube (Nalgene, Corning, NY) and flash 
frozen in liquid nitrogen after removal from the operating suite. Each tumor tumor was 
homogenized by crushing in a liquid nitrogen cooled Biopulverizer (BioSpec Products, 
Bartlesville, OK) mortar and pestle until particles were sub-millimeter size. A 10 mg 
sample of this powder from each tumor was reserved for RNA extraction and placed at -
80°C. The homogenized tumor tissue was separated into aliquots by weight in sterile 15 
mL conical tubes, and then suspended in PBS (Gibco, Life Technologies, Carlsbad CA) 
mixed with 10 µg/mL PMSF (Roche, Basel, Switzerland) in isopropyl alcohol, with 1% 
formaldehyde for cross-linking. Tumors were cross-linked for 15 minutes, rocking at 
room temperature, then washed with PBS + PMSF two times, centrifuging at 4°C, 500 g 
in between washes. Cross-linked tumors were flash frozen in liquid nitrogen and stored at 
-80°C until processing.  
Samples were lysed in two steps to produce a crude preparation of nuclei. On ice, 
samples were resuspended in Farnham’s lysis buffer (5 mM PIPES, 85 mM KCl, 0.5% 
NP-40), using 1 mL of buffer per IP. Tissue was dissociated into a single cell suspension 
using a 15 mL glass dounce (Wheaton), then incubated on ice for 10 minutes. Cells were 
centrifuged at 1200 g at 4 degrees for 10 minutes, and the pellet of mostly pure nuclei 
was gently resuspended in RIPA buffer (1x PBS, 1% NP-40, 0.5% Na Deoxycholate, 
0.1% SDS) with protease inhibitors (COmplete EDTA-free tablets, Roche, Basel, 
Switzerland) to lyse for 10 minutes, again on ice, 500 µL RIPA per IP. The crude lysate 
was aliquoted (500 µl/tube) into polystyrene 15 mL conical tubes, and the tumors were 
sonicated in an ice bath, 30 seconds on, 60 seconds off, high intensity (Bioruptor, 
 41 
Diagenode, Denville, NJ). Sonication continued for 4 ten-minute cycles, with ice being 
replaced after each cycle. Tumors were centrifuged at 500 g at 4°C for 2 minutes to 
collect condensate, then transferred to microcentrifuge tubes and centrifuged at maximum 
speed (21000 g) for 15 minutes at 4°C.  
Supernatant was transferred to fresh tubes, and volumes were brought up to 1 mL 
using RIPA buffer. For IP samples with rabbit antibodies, we used 30 µl of packed 
protein A beads per IP (Roche, Basel, Switzerland) as follows. Beads were washed three 
times in PBS plus 5 mg/mL BSA and protease inhibitors, with a 30 second centrifugation 
at 100 g in between washes. For each IP, 60 µl of resuspended beads in fresh wash 
solution were added, and samples plus beads were rocked for 30 minutes at 4°C. Samples 
were centrifuged at 100 g to pellet the beads, and the supernatant was transferred to a 
new tube. An input sample was removed at this stage (100 µl, 10% of total input) and 
antibodies were added for overnight incubation and rocking at 4°C. We performed the 
following IPs for each tumor: CTCF (EMD Millipore, Billerica, MA, USA, 07-729), 
H3K4me3 (EMD Millipore, 07-473), H3K4me1 (EMD Millipore, 07-436), H3K27me3 
(EMD Millipore, 07-449), H3K9ac (EMD Millipore, 07-352), H3K9me3 (abcam, 
Cambridge, MA, USA, ab8898), H3K27ac (abcam, ab4729), using 10 µg of antibody per 
IP.  
After the overnight incubation, we prepared protein A beads as before and added 
60 µl of beads to each IP. Tumors plus beads rocked for an hour at 4°C, followed by six 
successive washes performed at 4°C. Each wash rocked for five minutes and beads were 
pelleted as described previously. Washes were performed in the following order: 2x low 
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salt buffer (0.1% Na Deoxycholate, 1% Triton X-100, 1 mM EDTA, 50 mM HEPES (pH 
7.5), 150 mM NaCl), 1x high salt buffer (0.1% Na Deoxycholate, 1% Triton X-100, 1mM 
EDTA, 50 mM HEPES (pH 7.5), 500 mM NaCl), 1x lithium chloride buffer (250 mM 
LiCl, 0.5% NP-40, 0.5% Na Deoxycholate, 1 mM EDTA, 10 mM TrisCl (pH 8.1)), 2x 
Buffer TE (10 mM TrisCl (pH 8.1), 1 mM EDTA).  
To elute the antibody/DNA complexes from the beads, we resuspended the 
washed beads in 250 µl of freshly made 1% SDS and 0.1 M NaHCO3 buffer, and did the 
same with the frozen input sample. We rocked the samples for 15 minutes at 25°C, then 
collected the supernatant in a fresh tube and repeated the bead elution with an additional 
250 µl of buffer. From here, we added 20 µl of 5M NaCl to each sample, and incubated 
the samples for at least 4 hours at 65°C in a water bath to reverse the formaldehyde cross-
linking. We either froze the samples at -20°C or directly proceeded to the below steps for 
DNA extraction. 
Samples were brought to 25°C and any residual RNA was removed by adding 5 
µl 0.5 mg/mL RNase A to each tumor, then incubating for 30 minutes at 37°C. To digest 
proteins, we added 20 µl of 1 M Tris at pH 6.8, 10 µl 0.5 M EDTA, pH 8.0 and 3 µl 20 
mg/mL Protease K to each tumor, then incubated them at 55°C for one hour. Samples 
were extracted with phenol-chloroform and precipitated with ethanol. We resuspended 
the DNA pellet in 15 µl sterile DNase and RNase free water (Ambion), and quantitated 
the DNA using a Qubit and Qubit HS DNA kit (Q32851, Life Technologies, Carlsbad 
CA, USA). 
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qPCR ChIP enrichment quantification and primers 
To independently verify ChIP enrichments, we performed qPCR using positive 
and negative controls, as well as an input standard curve. We based the input standard 
curve on the percentage of input signal, and diluted the 10% input samples to produce 
data points at 1%, 0.1%, 0.01%, 0.001% and 0.001% (1:10, 1:100, 1:1000, 1:10000, 
1:100000 dilutions, respectively). This was used to calculate a fold enrichment of the IP 
sample relative to input. Sequences for all primers used in this study are located in Table 
2.4, below. We used Power SYBR Green PCR Master Mix (4367659, Applied 
Biosystems, Foster City, CA, USA) in 5 µl reactions and ran all plates on a ViiA7 RUO 
Real-Time PCR system located in the DNA Core facility at UT Austin. 
Primer name Sequence 
Size 
(bp) Amp. region hg38 Function 





HK4me3-1R TGCTGTGCTCGCAACTTCGC       



































NegCtrl-R CGATGACAGTGCTTCTCTGG       
Table 2.4: qPCR primers used in this study. 
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Library preparation and sequencing 
After quantitating the total DNA from each IP and assessing qPCR enrichment at 
positive control target sites, we prepared libraries according to the New England Biolabs 
NEBNext library prep kit (E6240L, New England Biolabs, Ipswich, MA, USA), with 
several changes to improve efficiency. We performed adapter ligation before size 
selection, we used Bioo adapters (514103, Bioo Scientific, Austin, TX, USA), and 
Ampure XP beads (A63881, Beckman-Coulter, Brea, CA, USA) in place of columns to 
do all reaction purifications and size selections. Generally, we also adjusted the number 
of cycles of PCR amplification to be as low as possible, often 6-8 cycles if feasible. Our 
sequencing was performed using standard Illumina chemistry on a HiSeq 2500 in either 
the Genome Sequencing facility at MD Anderson Cancer Center at Science Park 
(Smithville, TX) or the UT Austin Genome Sequencing and Analysis Facility (GSAF). 
Alignment and peak calling in ChIP-seq data 
Illumina paired-end sequencing of ChIP-seq libraries produced datasets for 7 
marks: 6 histone marks (H3K4me1, H3K4me3, H3K9ac, H3K9me3, H3K27ac, 
H3K27me3) and the CTCF transcription factor, for 11 tumors. Sequencing of input 
libraries was also performed for each tumor. BWA (v0.7.12-r1039)[143] was used to 
align all ChIP-seq and input sequence data.  All reads were hard-trimmed to 50 bases, 
and the aln and sampe commands from BWA were used to align the data to the hg38 
(GRCh38) assembly from GENCODE version 24.  We used the MarkDuplicates tool 
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from the Picard suite (v1.123) (http://broadinstitute.github.io/picard) to flag duplicate 
sequences. 
Given that ChIP-seq data can be variable from experiment to experiment with 
regard to signal depth, signal to noise ratio and read duplication levels, we used the 
Phantompeakqualtools v2.0 [144] tool from ENCODE.  This tool reports a normalized 
strand cross-correlation coefficient (NSC), and we recorded this value while allowing 0, 1 
or 2 duplicate reads.  From this analysis, we determined that allowing 1 duplicate read 
resulted in the best tradeoff between adequate signal strength (indicated by an NSC value 
of at least 1.05) and minimizing signal covariance across each set of tumor experiments. 
To identify enriched regions (peaks) in our ChIP-seq data, we utilized the 
MACS2 (v2.1.1.20160309)[145]  callpeak function.  We specified a relaxed P-value 
threshold of 0.01, and allowed one duplicate read per locus (keep-dup=2), with each 
ChIP-seq sample being paired with its input control library.  We removed any peaks 
falling in genomic regions with high signal due to high copy number differences [146] 
using bedtools intersect with the –v option.  Additionally, we removed low-complexity 
regions using the “Duke Excluded Regions” and “DAC Blacklisted regions” tracks from 
the UCSC genome browser 
(http://genome.ucsc.edu/cgibin/hgTrackUi?hgsid=334775099&c=chrX&g=wgEncodeMa
pability) and lifted these regions over to the hg38 genome assembly [147]. 
After initial peak calling, statistics were gathered; these included peak counts at a 
wide range of MACS2-reported Q-value and fold enrichment (FE) levels, and total 
coverage of the hg38 genome for each FE level.  P-values and Q-values were strongly 
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affected by sequencing depth for an experiment; we found that FE was more robust and 
less variable as a measure to define signal thresholds across each set of experiments.  
Based on peak counts and genome coverage at several FE thresholds, we selected three 
significance thresholds: high (FE 6+), target (FE 4.5+) and low (FE 3.5 or 4).  The 
MACS2-generated “narrowPeak” format files were converted it a custom BED9+ format, 
with P-value and Q-value fields, FE, peak rank among all peaks in that experiment, and a 
significance level designator.  All reported results in this study were generated using the 
peaks at the target level (FE 4.5+).  We chose the above FE thresholds to balance 
between variance in FE across mark sets and genome coverage.  At the target FE 
threshold, most Q-values were < 0.01, with all being < 0.05. 
Finally, we used the MACS2 bdgcmp signal processing tool 
(https://github.com/taoliu/MACS/wiki/Build-Signal-Track) to generate genome-wide 
signal tracks.  We used the linear-scale fold-enrichment method to compute per-base 
scores (-m FE).  This process produced bigWig files which represent sequencing depth 
normalized fold enrichment of ChIP-seq peaks over input signal.  These were loaded into 
the UCSC Genome Browser [148] and visualized on the hg38 genome assembly to 
produce figures.  To prepare the data for building a model using ChromHMM, we 
collected the target level peaks (FE 4.5+) and bedtools merge was used on each 
individual bed file to combine any overlapping peak regions (v2.25.0)[149]. 
Chromatin states: systematic identification of histone co-localization 
From the above merged consensus peaks for each experiment, we used 
ChromHMM v1.12 [55] to build our 21 state model, using only tumor data (11 tumors, 7 
 47 
experiments per tumor, 77 total datasets used). We made a table of tumors and 
experiments and binarized our bed file peak data using the BinarizeBed functions, with 
the  “-center” and  “-peaks” options set. With our data binarized, we used the 
LearnModel function, with multithreading and iterations set to “-p 16 -r 200” with 21 
states on the hg38 assembly. We assessed the genomic coverage of each state using 
bedtools coverage on hg38. Finally, we re-affiliated our model states with peak fold 
enrichment scores by using bedtools intersect for each tumor and model state. To 
understand which genes are regulated by which states, we used the GENCODE [57] 
annotation, version 24, and used bedtools closest to identify the distance between 
chromatin states and the most proximal protein coding genes. For enhancers, we analyzed 
the closest gene even if it was very far away (1 Mb or greater), but for bivalent regions, 
the closest gene (and thus the bivalent domain associated with it) was not analyzed unless 
the distance was less than 500 bp. 
Assessing gene enrichments for common enhancer and bivalent states using DAVID 
In order to assess enriched pathways and terms for our common enhancer and 
bivalent domains, we utilized DAVID 6.8 [71]. We identified enriched terms using 
functional annotation clustering. The DAVID terms in Figure 2.8c and Figure 2.10a 
were derived from functional annotation clustering as follows. For each functional 
annotation cluster, the term encompassing the largest number of genes while still having 
a significant P-value by the Benjamini correction was chosen, and an additional term 
could be chosen from any given cluster if the terms did not describe redundant features. 
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Annotation clusters were skipped if they appeared completely redundant to any previous 
cluster, or non-significant by Benjamini adjusted P-value of less than 0.05. This process 
was continued until at most 10 significant terms were identified. 
RNA sequencing in solid tumors and cell lines 
During the initial tissue processing, an approximately 10-15 mg sample of 
crushed tissue was set aside for RNA extraction. Tumors were removed from the -80° 
freezer, then 1 mL of TRIzol reagent (15596-026, Thermo Fisher Scientific, Waltham 
MA, USA) was added to each tumor, and the standard TRIzol protocol was followed for 
RNA isolation. RNA concentration was quantified using the NanoDrop ND-1000 
(NanoDrop Products, Wilmington, DE, USA). The Ribo-Zero rRNA removal kit 
(MRZH116, Illumina, San Diego, CA, USA) was used to remove ribosomal RNAs, and 
the resulting RNA was used to prepare single-end or paired-end libraries with the 
NEBNext small RNA kit for Illumina (E7300S, New England Biolabs, Ipswich, MA, 
USA). The resulting libraries were run on an Illumina HiSeq 2500 as above. Nearly all 
cell line experiments were represented by two biological replicates, although some were 
represented by three replicates (NHA, U87MG, A172). 
We began pre-alignment processing of RNA-seq data by removing any 3’ 
Illumina adapters from fastq reads using cutadapt (v1.10)[150]; any sequences shorter 
than 36 bases after trimming were discarded.  For experiments with fastq data from more 
than one sequencing lane, files were combined.  Reads from rRNA and tRNA were 
removed by aligning to a reference containing human rRNA and tRNA sequences using 
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BWA (v0.7.12-r1039)[143], then retaining sequences that did not align.  Tophat2 
(v2.1.0)[151] was used to align the remaining sequences in a transcriptome-aware 
manner, aligning to the hg38 (GRCh38) assembly, using GENCODE release 24 to build a 
comprehensive gene annotation set.  We used the MarkDuplicates tool from the Picard 
suite (v1.123) (http://broadinstitute.github.io/picard) to identify duplicate sequences in 
the resulting BAM files. 
We utilized the Tuxedo suite [152] to perform transcript FPKM quantification on 
RNA-seq datasets.  Each sample was quantified using cuffquant (cufflinks v2.2.1), using 
GENCODE version 24 annotations and specifying the –multi-read-correct and –frag-
bias-correct options.  The resulting cuffquant CBX files were gathered and processed 
together using cuffnorm (cufflinks v2.2.1), utilizing the geometric normalization method.  
We produced two sets of normalized data:  one for tumors and cell lines, and another for 
only tumors.  The resulting genes.fpkm_table files were used for subsequent FPKM 
expression analyses, including differential gene expression analysis. 
Assignment of TCGA subtypes to tumors 
To identify the TCGA molecular subtype of each tumor in this study, we 
extracted the ENSEMBL gene IDs from the 841 gene names from the TCGA subtyping 
study [58] (extracted from their supplementary file 
TCGA_unified_CORE_ClaNC840.txt).  Against our cuffnorm data we identified 743 
direct matches.  We identified another 92 matches using HGNC name information, as 
some gene identifiers had changed between hg18 (the genome version used for the 2008 
TCGA study) and hg38 (the version used in this study).  The final result was 836 
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matches.  FPKM values for the matching genes were extracted and ordered in the same 
manner as in the TCGA clustered data.  In R, we processed the resulting matrices as 
follows: missing or 0 values were replaced by the smallest R double precision value, the 
resulting matrix was log2 transformed, rows were median centered and complete 
Spearman pairwise correlation of columns was performed to identify a matrix of 
differences.  Finally, average-linkage hierarchial clustering was performed on the 
columns represented by the distance matrix – we assigned the TCGA subtypes 
mesenchymal, classical, and proneural to the tumors based on the three main branches of 
the resulting dendrogram. 
Differential gene expression analysis 
Based on the above assignment of TCGA subtypes to the samples used in this 
study, we performed differential gene expression analysis.  Based on enhancer and 
bivalent expression patterns, we identified genes differentially expressed between 
mesenchymal/classical and proneural tumors using cuffdiff (cufflinks v2.2.1).  We 
utilized the geometric normalization method, the pooled dispersion method, a minimum 
alignment count of 4, and the  multi-read-correct and  frag-bias-correct options.  Group 
assignments were as follows: mesenchymal/classical: AA1, GBM3, GBM5, GBM7, 
GBM8, GBM9; proneural: AA2, GBM1, GBM2, GBM4, GBM6. Genes described as 
significantly differentially expressed between mesenchymal/classical versus proneural 




Chapter 3: Differential expression in GBM tumors and GBM-derived 
cell lines 
 
Cultured cell lines derived from primary tumors have drastically increased 
mechanistic knowledge of cancer proliferation through their use as an in vitro model of 
many cancers.  However, the act of culturing tumor-derived cells long term introduces 
widespread genetic and epigenetic changes in cellular identity [5, 6].  These changes are 
caused in part by the lack of a stromal microenvironment in the case of solid tumors, such 
as cancers of the breast, brain, and thyroid [153].  Tumors are removed from their 
complex three-dimensional, often necrotic and/or hypoxic environment into an 
environment with a surplus of growth factors, including glucose, and passaged under 
atmospheric, not physiological oxygen levels.  We identified widespread gene expression 
changes in commercially available GBM-derived cell lines when compared to primary 
GBM tumors.  Of the 4945 genes that were significantly upregulated in GBM primary 
tumors, 394 are consistently expressed in the GBM-derived cell lines examined and are 
enriched for genes governing cell motility, as well as chromatin remodeler and kinases. 
INTRODUCTION 
In glioblastoma multiforme (GBM), cultured GBM-derived cell lines have existed 
since 1969 [154, 155], however recent studies have established that cultured glioma stem 
cells (GSCs) may be a better model of GBM [156, 157].  Cultured GSCs recapitulate 
certain aspects of tumor subtype – GSCs cultured from mesenchymal tumors have a gene 
expression pattern that reflects this subtype, and the same is true for proneural lesions as 
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well [81, 158-160].  Despite the existence of this improved in vitro model, establishing 
primary GSC culture from GBM tumors is not a trivial protocol [161-163].  As a result, 
many researchers continue to use decades old, commercially available GBM-derived cell 
lines.  Their culture conditions are simple (defined media and fetal bovine serum), and as 
a result there are thousands of publications that rely on the seven cell lines used in this 
study (counts from Pubmed searches for the following terms on 4/3/17: U87MG = 1613; 
T98G = 1074; A172 = 642; LN229 = 194; LN18 = 91; U118MG = 62; U138MG = 58).  
Many of these studies were published after 2015, so this is not just reflective of an older 
model being superseded by a new model over time.   
Despite the existence of superior in vitro models of GBM, much bench work is 
still reliant on a small group of immortalized cell lines. Given the widespread changes in 
cellular identity induced by cell culture [164], and the issues with reproducibility and 
relevance widespread in biomedical research [165], researchers need to be able to justify 
the use of a given cell line as a disease model.  Quantification of the differences between 
primary tumor samples and immortalized cell lines will allow for the more judicious use 
of these lines.  By understanding which genes and pathways in each cell line most closely 
resemble gene expression in primary tumors, experiments in these lines can be assessed 
for their clinical relevance in cultured GSCs or primary tumor samples. 
RESULTS 
There are 4945 genes that are significantly upregulated in tumors 
 As part of examining gene expression in cell lines to determine their suitability 
for subtyping (Figure 2.2), we examined gene expression across all protein-coding genes, 
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Figure 3.1: Tumor vs. cell line expression over all protein coding genes 
Spearman’s rho was used to cluster rows and columns over 32 RNA-seq datasets from 11 
brain tumors, two meningiomas, normal human astrocytes (NHA) and 7 GBM-derived 
cell lines available from ATCC.  Protein-coding genes were defined using GENCODE 
version 24.  For the cell line and NHA data, at least two biological replicates were used. 
 
in the 32 RNA-seq samples produced and described in Chapter 2.  The clustered 
expression matrix revealed stark differences in gene expression between primary tumors, 
normal human astrocytes and immortalized GBM-derived cell lines (Figure 3.1).  
Despite these gross differences, there are groups of genes in each cell line that mimic the 





Figure 3.2: 4945 genes are upregulated in tumors compared to cell lines 
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Figure 3.2: 4945 genes are upregulated in tumors compared to cell lines 
 
(a) Box plot of FPKM gene expression values over the 4945 genes that were upregulated 
in tissue for all RNA-seq experiments. Data have been normalized to remove the 
confounds of sequencing depth using cuffnorm, and significantly upregulated genes were 
identified using cuffdiff, with a Q-value threshold of less than 0.05.   
(b) A heatmap of the log2 transformed data in a. An expression heatmap of 4945 genes 
significantly up in tumors, over all RNA-seq datasets.  Data are clustered using 



















Given the visually obvious differences in expression between tumors and cell 
lines, we systematically identified differentially expressed genes across these groups 
using cuffdiff (Methods).  Using tumor samples as one group, and cell lines as another 
group, we identified 4945 genes that are significantly more highly expressed in tumors, 
and 1416 genes that are significantly more highly expressed in cell lines.  For the genes 
were significantly upregulated in tumors, the expression for the cell lines was much 
lower, but there was some overlap in the distribution (Figure 3.2a).  This indicates that 
the majority of tumor-specific genes are minimally expressed, but each cell line contains 
a subset of genes where expression is more similar to the tumors.  This trend is visible in 
the heatmap in Figure 3.2b. 
 To identify tumor specific genes that are expressed in the GBM-derived cell lines, 
we used the R package “reshape2” (https://github.com/hadley/reshape) to melt the cell 
line expression data into a “long” format, where rows represent all cell line-gene-FPKM 
combinations.  Since the median FPKM for tumor-specific genes was 3.7 across all 4945 
genes and 13 samples (Figure 3.2a), this cutoff was used to select cell line-gene-FPKM 
combinations.  This threshold resulted in 2025 genes where cell line expression is at least 
at or above the median tumor level of expression, and 2920 genes where cell line 
expression is below the median tumor expression (Figure 3.3). 
394 genes are highly expressed in all GBM-derived cell lines 
 Over the 2025 genes that are tumor-specific, but expressed in cell lines, the sets of 
genes specific to each cell line were identified.  Interestingly, 394 genes passed the 
threshold in all seven cell lines (Figure 3.4a,b).  These genes represent commonalities in 
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Figure 3.3: Identifying tumor specific genes expressed in GBM cell lines 
RNA-seq data from cell lines was separated into genes expressed above and below the 
median tumor FPKM for upregulated genes (3.7).   
(a) Box plot of FPKM values for tumors, and cell line data after filtering for gene-value 
pairs with an FPKM above 3.7.  
(b) A heatmap representation of the 2025 tumor specific genes that passed the FPKM 
threshold for cell lines. 
(c) The 2920 tumor-specific genes that didn’t pass the FPKM threshold (cell line 
expression is below the median) 
 
expression for all tumors and GBM-derived cell lines, so the genes and pathways may be 
the most reflective of primary tumor expression in studies that rely on these cell lines.  
The DAVID terms enriched in this set were diverse, and indicated common expression of 
GAP proteins, many of which are involved with cytoskeletal reorganization.  The large 
number of proteins containing pleckstrin homology-like domains [166], as well as SH3 
domains [167] and microtubule or cell junction interaction corroborates this signature 




Figure 3.4: Identification of 394 genes expressed in all cell lines 
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Figure 3.4: Identification of 394 genes expressed in all cell lines 
 
(a) A heatmap of the 394 genes that were commonly identified as being above the 3.7 
FPKM threshold in Figure 3.3. 
(b) A boxplot of the data represented by the heatmap in a. 
(c) Enriched DAVID terms for the 394 genes represented in a and b. 
(d) Interactions between the 394 genes, as identified through StringDb [72].  This 
network comprises 167 nodes and 337 edges.  Node size is a function of the number of 
connected edges, and edge weight represents the confidence of the interaction between 



















ubiquitin ligases (RNF19A, DTX3, UBR3, MIB2, MARCH6) or chromatin remodelers.  
The chromatin remodelers contained both bromodomain proteins (BAZ2A, BAZ2B, 
BPTF) and histone modifying enzymes (ASH1L, PHF21A, KMT2C, KDM2A, KMT2E, 
HDAC6, EP300). 
 Given the overlapping DAVID terms, these genes were assessed for their 
interconnectivity using interaction data from StringDb [72].  The resulting network was 
highly interconnected, with 167 genes being interconnected by 337 edges (Figure 3.4d).  
The connectivity was distributed, with 14 genes having at least 10 edges.  These hubs 
formed three distinct groups: kinases and their effectors (FYN, EGFR, PTK2, PAK1, 
EPS15), chromatin remodelers/transcriptional regulators (EP300, NCOR2, HDAC5, 
POLR2A), and GTPase regulators and exchange factors (ABR, ARHGEF7, ARHGEF12, 
TRIO, ITSN1).   
DAVID enrichment for each GBM-derived cell line 
 We identified lists of tumor-specific genes above the FPKM threshold in each cell 
line.  From these lists we subtracted the 394 genes that are consistently up, described in 
the previous section, to avoid background from the genes and terms indicated in Figure 
3.4. Each cell line presented the “cell junction” and “pleckstrin homology-like domains” 
DAVID terms, but other terms seemed more specific (Figure 3.5).   
Normal human astrocytes (NHA), which are cultured but non-immortalized, were 
enriched for the immunoglobulin I-set and C2H2 zinc fingers.  The microglial cell line 
U87MG is enriched for C2 domains and presynapse formation.  The U138MG cell line 
(listed with U118MG as they are identical [168]) seems to have some specific enrichment  
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Figure 3.5: DAVID enrichment in each GBM-derived cell line. 
 
The 394 genes common to expression in all cells line were removed from the gene set for 
each cell line analyzed, and the remaining gene IDs were examined using DAVID 6.8.  
The top terms from the Functional Annotation Clustering tool were aggregated as 
described in the Chapter 2 methods, with no more than 10 significant terms being 
accumulated for any given cell-line. 
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for endocytosis and metal binding. LN18 only has the generic term “transcription” as a 
unique feature, while LN229 has enrichment for SH3 domains (along with U138MG) and 
positive regulation of GTPase activity.  A172 is enriched for membrane specific proteins 
and post-synaptic density, and the commonly used cell line T98G is enriched for the 
thyroid hormone signaling pathway.   Three groups (U118/U138, LN229, LN18) contain 
the term “WD40/YVTN domain”, which is a propeller shaped domain often used as a 
scaffold for large multiunit complexes [169]. 
DISCUSSION 
Although GSCs are an effective in vitro model for GBM, their specialized culture 
conditions indicate they are currently less likely to be used than commercially available 
cell line models of GBM.  These cell lines do not resemble primary tumors in their 
expression patterns (Figure 3.1), however, given their widespread use as models of 
cancer, it is useful to identify which genes are commonly expressed in tumors and cell 
lines.  Using the Tuxedo Suite [152], we identified 4945 genes significantly upregulated 
in primary GBM tumors, and examined which of these genes were expressed in each cell 
line (Figure 3.2, Figure 3.3). 
We identified 394 genes that were highly expressed in tumors and cell lines 
(Figure 3.4) and found the resulting gene interaction network to be highly and diffusely 
interconnected, with 14 genes having at least 10 connections.  These hub genes clustered 
into three groups: kinases, GTPase regulators and exchange factors, and chromatin 
remodelers.  Many of these genes have a prior association with GBM. 
The kinase hub genes (FYN, EGFR, PTK2, FAK1, EPS15) are all involved in 
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cellular migration and adhesion in some fashion.  EGFR is well known in GBM [170], so 
its presence is not surprising, however EPS15 is involved in the recycling of EGFR [171], 
and expression of EPS15 is associated with a favorable prognosis in breast cancer [172] 
and lung cancer [173].  The non-receptor tyrosine kinase FYN is necessary for cellular 
migration in GSCs [174], and is an effector of EGFR [175].  The tyrosine kinase PTK2 is 
involved in cell migration and motility, its inhibition reduces the aggressiveness of GBM 
cells [176].  Finally the serine-threonine kinase PAK1 (also known as P21) is involved in 
myriad aspects of cell proliferation and migration, and is also implicated in the 
invasiveness of GBM [177]. 
 The genes annotated as chromatin remodelers (EP300, NCOR2, HDAC5, 
POLR2A) are a mixed group, with some being activators and others repressors.  EP300 is 
a histone acetylase, and drives cellular differentiation, and its expression in GBM is 
associated with an improved prognosis [178].  Nuclear co-repressor 2 (NCOR2) promotes 
chromatin condensation, and when targeted by an antagonistic microRNA (miR-100), 
cell proliferation is reduced [179].  In breast cancer, NCOR2 expression is associated 
with resistance to anti-estrogen therapies, such as tamoxifen [180].  Expression of 
HDAC5 is positively correlated with survival in GBM [181], but in other cancers, 
expression is associated with cellular proliferation and metastasis [182-185].  The 
presence of RNA polymerase II alpha subunit (POLR2A) is likely indicative of cells that 
are actively proliferating, but its ubiquity as part of the transcriptional machinery means 
that further associations are difficult to ascertain. 
 Of the GAP and GEF proteins (ABR, ARHGEF7, ARHGEF12, TRIO, ITSN1), two 
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have a strong association with GBM.  TRIO is a Rho GEF involved in actin-cytoskeleton 
reorganization, and mediates the invasive behavior of GBMs [186, 187].  ITSN1 acts as a 
GEF for CDC42, and is essential for GBM proliferation [188].  ABR and ARHGEF7 have 
no documented cancer associations, however ARHGEF12 regulates cell morphology and 
invasion [189], particularly with regard to colorectal cancer [190]. These hub genes 
indicate cross talk between pathways mediating cytoskeletal reorganization, chromatin 
modification and cellular proliferation. 
 For genes specific to each cell line, the DAVID enrichments are relatively non-
specific, but capture many genes.  From a pathway perspective, cell junctions, pleckstrin-
homology domains, and GTPase activity or GEF terms indicate that cellular migration 
and cytoskeleton remodeling are important forces governing growth in these lines.  While 
the terms are the same, the genes associated with terms differ somewhat by cell line, thus 
this data should be valuable for determining which cell line to use in an experiment, 
given the genes or pathways of interest.  The vast majority of DAVID terms are not 
unique to a single cell line – most occur in at least three datasets (Figure 3.5).  While 
each cell line contains tumor specific genes that are also specific to expression in that cell 
line, the number of gene identifiers is low (less than 100) such that there is insufficient 
statistical power for any resulting DAVID term to be significant.  
 In summary, we have determined that the expression of primary GBM tumors and 
immortal cell lines derived from GBM tumors are widely divergent.  A small subset of 
genes in each cell line align with expression of 4945 tumor-specific genes, and 394 of 
these genes are common to all seven cell lines examined in this study.  To extend this 
 65 
analysis, obtaining and normalizing GSC and additional GBM expression data will 
further define changes in gene expression with regard to comparing primary tumors and 
cultured material.  As certain immortal GBM-derived cell lines have been cultured as 
neurospheres [191, 192], comparison with these data would also indicate how using 
advanced culture conditions can improve the clinical relevance of commercially available 
cell lines. 
Cultured cell lines provide a powerful and flexible system for validating the 
activity and effects of genes, mutations, and pathways identified in clinical cancer data.  
As tumor samples are generally precious and limited in supply, cell lines provide an easy 
way to interrogate cellular response when various genetic pathways are manipulated.  
Cultured cell lines also provide ample source material for validating the activity of 
enhancers and other genomic elements using techniques like luciferase assays.  These 
methods are invaluable for validating initial results from clinical pathology and mutation 
analysis.  However, given the widespread differences in expression evident when 
comparing clinical tumor samples to cultured cell lines, careful thought must be given to 
how cell lines recapitulate models of disease. 
Glioma stem cells (GSCs) and other “sphere” based cultured methods use more 
complex cultured conditions than most immortalized lines.  These conditions are more 
expensive and time-consuming to maintain, but also result in a much more biologically 
relevant model system, especially with regard to testing therapeutic options.  However, 
immortalized cell lines, when cultured in standard conditions, are excellent workhorses 
for validating cell proliferation in the context of pharmacological inhibitions.  Given this, 
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a dual use model of in vitro cell line use may make the most sense.  Use immortalized 
cell lines to rapidly screen for compounds of interest, but validate the most promising 
findings in a more complex model of GSCs (or the appropriate “sphere” culture model 
for the cancer or tissue under study). 
MATERIALS AND METHODS 
RNA sequencing and analysis, differential gene expression analysis, and DAVID 
annotation of functional terms were performed as described in the Chapter 2 Methods 
section. 
Cell lines and culture conditions 
The following cell lines were purchased from ATCC (Manassas, VA, USA): 
U87MG (HTB-14), U138MG (HTB-16), U118MG (HTB-15), LN18 (CRL-2610), 
LN229 (CRL-2611), T98G (CRL-1690).  Upon arrival in the lab, frozen vials were 
revived as specified by ATCC, and cells were cultured according to standard conditions 
specified by ATCC.  Approximately 10 million cells were harvested at approximately 
70% confluency for RNA extraction as described in Chapter 2 Methods. 
Normal human astrocytes (NHA) were purchased and cultured as specified (CC-
2565, Lonza Inc, Allendale, NJ, USA).  RNA sequencing was performed when NHA1 
was at a population doubling of 3.5 (NHA1 B1) and 7 (NHA1 B2), and for NHA2 the 




Chapter 4: Novel association of polymorphic genetic variants with 
predictors of outcome of catheter ablation in atrial fibrillation: new 
directions from a prospective study (DECAF)1 
Genome-wide association studies (GWAS) have allowed the genetics of disease 
to move beyond the Mendelian “one-gene/one phenotype” model [193].  However, many 
of the SNPs associated with affected phenotypes are located in non-coding regions of the 
genome, making the mechanistic effect of such SNPs difficult to determine.  Any single 
SNP discovered in this fashion may only confer a small amount of risk, thus necessitating 
an understanding of how such SNPs affect gene expression during development and in an 
adult to cause a disease phenotype in an individual. 
The ENCODE project and similar consortia have vastly increased the amount of 
genomic data available in a number of widely used cell lines, some immortal, some 
primary, as well as healthy human tissues [4, 194].  These data provide a window into the 
non-sequence based human genome, and allow us to see regulatory functions of DNA. 
Identifying the regulatory regions proximal to a non-coding but risk associated SNP 
allows for some elucidation of which regions of the genome may function synergistically 
[195].  Identifying which genes or transcripts are located on the same topologically 
associated domain (TAD) as the SNP in question decreases the search space for 
mechanistic effects, and limits which genes may be affected by a given SNP [196]. 
                                                
1This work was published in Mohanty S1, Hall AW1 et al., Novel association of polymorphic genetic 
variants with predictors of outcome of catheter ablation in atrial fibrillation: new directions from a  
prospective study (DECAF). J Interv Card Electrophysiol. 2016 Jan;45(1):7-17. VRI, AWH and MM 
conceived the study and designed the experiments. AWH performed the experiments, collected the data and 




Atrial fibrillation (AF) is an intriguing model for understanding the effects of risk-
associated SNPs for several reasons:  it is relatively common, with 2% of the US 
population affected (~6 million individuals, [197]), it is relatively easy to diagnose an AF 
episode using an EKG, and there are numerous GWAS SNPs associated with AF.  While 
AF is comparatively easy to identify during an episode, treatment remains a more 
difficult prospect. Catheter ablation is a relatively recent noninvasive surgical option for 
treatment of AF that involves mapping the electrical conductivity of the heart using 
catheters that enter the body through the femoral vein.  Areas of aberrant electrical 
activity are ablated using high frequency radio waves to prevent the arrhythmia from 
occuring in the future.  Several drugs exist for controlling arrhythmias, but all have a 
substantial risk of side effects.  As such, catheter ablation is emerging as a superior 
option for long-term treatment of AF [198, 199].   
However, catheter ablation has an initial success rate of 67-77% for the first 
procedure, with higher success rates only occurring after multiple ablations [200].  There 
are several reasons for this variability in response to catheter ablation: advanced age, 
metabolic syndrome, preexisting scarring in the left atrium, and triggers originating from 
non-pulmonary vein sites (non-PV), all contribute to adverse outcomes following catheter 
ablation [201-203].  The common comorbidies indicate that individuals can be 
genetically predisposed to AF.  The first GWAS for AF was published in 2007 [204], and 
identified the SNP rs2200733, located on chromosome 4q25, as a risk allele associated 
with AF.  Since then, a number of additional GWAS for AF have concluded, and 
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identified a number of additional SNPs associated with AF risk [205-208].  However, 
these studies are comparisons of cases and controls, and do not allow for examination, in 
a population of individuals with AF, what SNPs may be determinants of response to 
treatment.  Therefore, we designed the prospective study: Determining the association of 
chromosomal variants with non-PV triggers and ablation-outcome in AF (DECAF).  
Here, we examined the effects of 16 GWAS SNPs associated with AF on individual 
response to catheter ablation therapy, coupled with metadata on patient phenotypes such 
as left atrial scar and non-PV triggers. 
RESULTS 
371 patients with AF were genotyped and assessed for AF characteristics 
400 consenting patients scheduled to undergo cardiac ablation were enrolled in 
the study, and blood was collected as described in the methods section.  Genomic DNA 
isolation and genotyping was attempted for all 400 samples and 29 samples were 
excluded due to a lack of consensus during genotyping or low quality DNA.  371 samples 
were successfully genotyped and included in this analysis, and the characteristics for this 
population are described in Table 4.1.  We collected data on the location of the AF 
trigger sites in each patient, and for many (but not all) patients, the presence of left atrial 
scarring.  Non-PV triggers were detected in 40 (27 %) patients with paroxysmal AF 
(PAF), 123 (70 %) persistent AF, and 46 (92 %) long-standing persistent (LSP) patients. 
Information on presence of LA scar at the time of ablation procedure was available for 
276 patients; LA scar was observed in 40 of 99 (41 %) PAF patients, 87 of 134 (65 %) 










Table 4.1: Characteristics of the study population (n = 371). 
CVA cerebrovascular accident, TIA transient ischemic attack, LVEF left ventricular 
ejection fraction, LSP long-standing persistent AF. 
 
SNPs associations with non-PV trigger present and absent 
 Three SNPs predicted some aspects of non-PV trigger risk (Table 4.2). The 
presence of non-PV triggers was associated with rs2106261 as well as rs6843082 for the 
additive model. rs2106261 is located in an intron of the gene ZFHX3, a transcriptional 
regulator involved in myocyte differentiation [209].  rs6843082 is associated with a risk 
of ischemic stroke [210], and is 150 kb upstream of PITX2, near the non-coding RNA 
LINC01438.  PITX2 delimits sinoatrial node formation in the developing heart through 
microRNA regulation [211].  For the SNP rs1448817, the group without non-PV triggers 
is substantially more likely to be homozygous for the minor allele genotype with the 
recessive model.  rs1448817 is 80 kb upstream of PITX2. 
 
Age, year 64±11 
Male  249 (67%) 
AF Type   
      Paroxysmal 146 (39%) 
      Persistent 175 (47%) 
      LSP 50 (13%) 
Body Mass Index 30±6.5 
Diabetes 82 (22%) 
Hypertension 245 (66%) 
Coronary Artery Disease 64 (17%) 
CVA/TIA 22 (5.9%) 
LVEF, % 57±9 
Left atrial size, cm 4.59±0.74 
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SNP Non-PV trigger      present (n=209) 
Non-PV trigger                        




AA Aa  aa AA Aa aa additive dominant recessive χ2 
rs11047543 
(A, G) 163 42 4 121 39 2 0.5491 0.4616 0.7000 0.5910 
rs13376333 
(T, C) 96 95 18 70 73 19 0.4790 0.6738 0.3831 0.5940 
rs1448817 
(G, A) 88 102 19 62 73 27 0.2596 0.5223 0.0381 0.0895 
rs16997168 
(T, C) 122 73 14 92 60 9 0.9189 0.8324 0.8286 0.8428 
rs17042171 
(A, C) 134 64 11 91 60 11 0.1017 0.1341 0.6586 0.2965 
rs17375901 
(T, C) 186 23 0 147 14 1 0.7365 0.6094 0.4367 0.4001 
rs2106261 
(T, C) 124 73 12 102 53 7 0.0011 0.5203 0.6722 0.7086 
rs251253 
(T,C) 29 108 71 24 80 58 0.8843 0.8814 0.6669 0.8884 
rs3807989 
(A, G) 86 89 32 66 79 17 0.9182 0.9153 0.2160 0.3064 
rs3825214 
(G, A) 135 69 5 111 48 3 0.4476 0.4404 1.0000 0.7163 
rs6599230 
(T, C) 127 69 13 90 59 13 0.2652 0.3397 0.5423 0.5615 
rs6666258 
(C, G) 96 95 18 70 73 19 0.4790 0.6738 0.3831 0.5937 
rs6843082 
(G, A) 105 85 18 67 72 23 0.0443 0.0929 0.0978 0.1091 
rs7164883 
(G, A) 142 60 6 104 53 5 0.4503 0.4381 1.0000 0.7096 
rs7193343 
(T, C) 117 80 12 103 52 6 0.0980 0.1353 0.4681 0.2661 
rs8192284 
(C, A) 70 103 35 65 73 23 0.1720 0.1926 0.5652 0.4016 
 
Table 4.2: SNP frequencies in non-PV trigger present and absent 
See Methods for the definitions of additive, dominant, and recessive models. 
 χ2, chi squared test.  Values in red are less than 0.05. 
Non-PV trigger in persistent and non-persistent AF 
 We identified one SNP associated with an absence of non-PV triggers in 
persistent AF (Table 4.3).  Persistent AF is non-episodic, and occurs constantly, or nearly 
so.  In the population surveyed here, non-PV triggers are more likely to be absent in 
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persistent AF, and studies of catheter ablation in patients with persistent AF recommend 
routine encircling of the pulmonary veins to improve the probability of success [212].  
Both rs7193343 and rs2106261 are located in the same intron of ZFHX3, separated by a 
stretch of 23 kb. 
 




AA Aa  aa AA Aa aa additive dominant recessive χ2 
rs11047543 
(A, G) 34 5 1 77 28 1 0.2060 0.1338 0.4743 0.1665 
rs13376333 
(T, C) 18 18 4 50 48 8 0.8580 0.8541 0.7364 0.8858 
rs1448817 
(G, A) 18 17 5 39 53 14 0.3660 0.4472 1.0000 0.6528 
rs16997168 
(T, C) 20 16 4 63 38 4 0.2097 0.3481 0.2165 0.2684 
rs17042171 
(A, C) 27 9 4 58 45 3 0.3755 0.1904 0.0896 0.0294 
rs17375901 
(T, C) 36 4 0 97 9 0 0.7519 0.7519 1.0000 0.7752 
rs2106261 
(T, C) 19 17 4 66 34 6 0.1073 0.1328 0.4621 0.2479 
rs251253 
(T,C) 7 22 11 16 53 37 0.6201 0.7997 0.4319 0.6933 
rs3807989 
(A, G) 20 15 5 46 50 10 0.5964 0.5764 0.5555 0.5611 
rs3825214 
(G, A) 29 11 0 75 30 1 0.8408 1.0000 1.0000 0.8202 
rs6599230 
(T, C) 25 13 2 67 33 6 1.0000 1.0000 1.0000 0.9789 
rs6666258 
(C, G) 18 18 4 50 48 8 0.8580 0.8541 0.7364 0.8858 
rs6843082 
(G, A) 24 12 4 46 50 10 0.1090 0.0947 1.0000 0.1576 
rs7164883 
(G, A) 28 10 2 71 32 3 1.0000 0.8433 0.6148 0.7012 
rs7193343 
(T, C) 17 19 4 65 35 5 0.0314 0.0406 0.2608 0.0921 
rs8192284 
(C, A) 14 22 4 43 51 11 0.5832 0.5714 1.0000 0.7768 
Table 4.3: Non-PV trigger present versus absent in persistent AF 
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 Several SNPs were significantly associated with the presence of non-PV triggers 
in the non-persistent AF group.  Four SNPs were associated with the presence of non-PV 
triggers using the recessive model: rs13376333, rs1448817, rs17042171, and rs6666258. 
rs13376333 and rs6666258 are 87 bases apart, located in an intron of the potassium 
calcium-activated ion channel KCNN3, involved in atrial repolarization [207]. rs1448817 
is upstream of PITX2, rs17042171 is in an intron of ZFHX3. 




AA Aa  aa AA Aa  aa additive dominant recessive χ2 
rs11047543 
(A, G) 129 37 3 44 11 1 0.8593 0.8553 1.0000 0.9383 
rs13376333 
(T, C) 78 77 14 20 25 11 0.0795 0.2137 0.0267 0.0512 
rs1448817 
(G, A) 70 85 14 23 20 13 0.5585 1.0000 0.0074 0.0077 
rs16997168 
(T, C) 102 57 10 29 22 5 0.2342 0.2770 0.5357 0.4788 
rs17042171 
(A, C) 107 55 7 33 15 8 0.2366 0.6337 0.0137 0.0292 
rs17375901 
(T, C) 150 19 0 50 5 1 0.8132 1.0000 0.2489 0.1989 
rs2106261 
(T, C) 105 56 8 36 19 1 0.6434 0.8736 0.4570 0.6210 
rs251253 
(T,C) 22 86 60 8 27 21 0.8272 0.8226 0.8727 0.9253 
rs3807989 
(A, G) 66 74 27 20 29 7 0.8780 0.6379 0.6680 0.5961 
rs3825214 
(G, A) 106 58 5 36 18 2 1.0000 0.8742 1.0000 0.9389 
rs6599230 
(T, C) 102 56 11 23 26 7 0.0081 0.0134 0.1618 0.0344 
rs6666258 
(C, G) 78 77 14 20 25 11 0.0795 0.2137 0.0267 0.0512 
rs6843082 
(G, A) 81 73 14 21 22 13 0.0452 0.2150 0.0075 0.0114 
rs7164883 
(G, A) 114 50 4 33 21 2 0.2092 0.2563 0.6414 0.4663 
rs7193343 
(T, C) 100 61 8 38 17 1 0.2157 0.2711 0.4570 0.4004 
rs8192284 
(C, A) 56 81 31 22 22 12 0.5383 0.4229 0.6956 0.5093 
Table 4.4: Non-PV trigger present versus absent in non-persistent AF 
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 Two additional SNPs were associated with the presence of non-PV triggers in 
non-persistent AF.  rs6599230 was associated with non-PV triggers in the additive and 
dominant models, while rs6843082 was associated with with non-PV triggers in the 
additive and recessive models. rs6599230 is a synonymous variant in an exon of SCN5A 
– the codon change from GCA to GCG keeps the residue an alanine in either case.  
Across the non-persistent AF group, three SNPs were also significantly different between 
the non-PV trigger present and non-PV trigger absent group for non-persistent AF, using 
the chi-squared test of independence (rs17042171, rs6599230, rs6843082). 
SNP association with LA scar risk 
 A single SNP is associated with an increase in the presence of scarring on the left 
atrium: rs3807989. This SNP is located in an intron of caveolin-1 (CAV1).  For AF, the G 
allele is associated with risk, however this SNP is also associated with differences in the 
PR interval (a measure of atrial and atrial ventricular node conduction [213]) and these 
traits are associated with the A allele [214, 215].  This SNP also tests with a low value for 
the chi squared test of independence, indicating that the incidence of this polymorphism 
between the LA scar present and LA scar absent groups is truly different. 
DISCUSSION 
 Although our population of patients with AF was small, several SNPs were 
associated with the overall presence of non-PV triggers in AF, as well as in persistent and 
non-persistent AF, and with left atrial scarring.  This is impressive given the total 
population surveyed is only 371 individuals.  However, when multiple testing corrections 
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are applied to this data, only a single SNP retains significance: rs2106261 for an overall 
association with the presence of non-PV triggers.  In larger studies of AF that retain 
metadata, it may be interesting to test for population specific associations of the above 
SNPs that did not survive multiple testing corrections. 
From a mechanistic perspective, none of the associated SNPs caused amino acid 
changes in protein-coding genes, so the mechanism of the risk effect is likely subtle. 
SNP LA Scar Present (n=156) 
No LA Scar              




AA Aa  aa AA Aa  aa additive dominant recessive χ2 
rs11047543 
(A, G) 121 33 1 90 28 2 0.4825 0.5677 0.5823 0.6515 
rs13376333 
(T, C) 70 70 16 54 53 13 1.0000 1.0000 1.0000 0.9855 
rs1448817 
(G, A) 60 79 17 46 59 15 1.0000 1.0000 0.7076 0.9139 
rs16997168 
(T, C) 96 52 8 65 41 13 0.1273 0.2677 0.1069 0.1698 
rs17042171 
(A, C) 95 53 8 71 42 7 0.8113 0.8048 0.7959 0.9434 
rs17375901 
(T, C) 137 18 1 110 10 0 0.3294 0.3291 1.0000 0.4565 
rs2106261 
(T, C) 90 58 8 69 43 8 0.9060 1.0000 0.6122 0.8560 
rs251253 
(T, C) 26 73 56 17 67 36 0.7440 0.6174 0.3048 0.3556 
rs3807989 
(A, G) 68 60 27 46 64 10 0.8116 0.3887 0.0326 0.0197 
rs3825214 
(G, A) 98 52 6 75 43 2 0.8074 1.0000 0.4725 0.5391 
rs6599230 
(T, C) 97 48 11 72 43 5 1.0000 0.8033 0.4372 0.4598 
rs6666258 
(C, G) 70 70 16 54 53 13 1.0000 1.0000 1.0000 0.9855 
rs6843082 
(G, A) 73 66 16 54 51 15 0.6424 0.8074 0.5713 0.9176 
rs7164883 
(G, A) 100 51 5 82 33 4 0.4556 0.4414 1.0000 0.6755 
rs7193343 
(T, C) 86 62 8 68 44 7 0.8133 0.8065 0.7949 0.8809 
rs8192284 
(C, A) 57 78 21 42 58 19 0.8070 0.8993 0.2226 0.8429 
Table 4.5: SNP associations for left atrial scar present versus absent 
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 rs13376333 and  rs1448817 are both upstream of the homeodomain gene PITX2. 
Increased expression of PITX2 is observed in cardiac myocytes from chronic AF patients, 
and this increased expression results in a decrease of the voltage-gated Ca++ current and 
increase of the slow delayed inward rectifying potassium channel current [216].  PITX2 is 
specifically expressed in the left atrium, and a change in expression causes increased 
susceptibility to AF rhythms [217]. An increase in WNT8 expression is implicated as the 
cause in in vitro models [218].  Mouse models with a knockout of PITX2 results in an 
impairment of the associated genes ZFHX3 (rs17042171, rs2106261) and KCNN3 
(rs13376333 and rs6666258). A knockdown of ZFHX3 is associated with 
arrhythmogenesis and disregulation of calcium homeostasis in atrial myocytes [219]. 
 This data captured one association with an increase in left atrial scarring 
(rs3807989), however this SNP has risk associations with both alleles across multiple 
GWAS studies [208, 213-215].  This makes a mechanism difficult to determine, but may 
indicate this locus is associated with modulation of a profibrotic response [220].  Fibrosis 
is frequently identified in the left atrium of long-term AF patients, and this is associated 
with activation of the EMT [221, 222].  The widespread changes in gene expression 
brought on by the existence of AF (likely associated with changes in PITX2 expression) 
may cause changes in tissue composition that change the electrical conductivity in the left 
atrium, disrupting the pacemaking activity of the sinoatrial node and causing arrhythmia. 
MATERIALS AND METHODS 
This prospective single-center pilot study enrolled 400 consecutive AF patients 
undergoing catheter ablation at Texas Cardiac Arrhythmia Institute, St. David’s Medical 
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Center, Austin, TX, from December 20, 2012, to August 30, 2013. Patients with bleeding 
disorders and inability to provide written informed consent were excluded from the study. 
Echocardiograms were performed on all patients before ablation to obtain measurements 
on LA diameter and left ventricular ejection fraction (LVEF).  Institutional protocol for 
standard mapping and ablation procedure was followed by all physicians as described in 
detail in our earlier publications [223]. The study was approved by our institutional 
review boards and registered at clinicaltrials.gov (NCT01751607). It was conducted in 
collaboration with department of Molecular Biosciences, University of Texas (UT) at 
Austin. 
Statistical Analysis 
We used R software for all statistical analysis (version 3.1.1).  We stratified the 
results by population into three groups: Non PV triggers present versus Non PV triggers 
absent, persistent AF versus non-persistent AF, and left atrial scar versus no left atrial 
scar.  For each SNP, we used three models of calculating the contribution of risk to each: 
recessive, dominant, and additive.  The recessive model only counts a genotype of “aa” 
or two recessive risk alleles as a success when calculating contingency tables.  The 
dominant model presumes any presence of the risk allele contributes to disease phenotype 
and counts “Aa” and “aa” genotypes as a success, values being held even for both.  The 
additive model counts “Aa” and “aa” as a success, but since the recessive genotype “aa” 
contains two copies of the risk allele, it is counted twice.  For these three models, for all 
data included in this study, we used Fisher’s Exact Test for count data to calculate P-
values, and also calculated the Chi-squared test for independence for each group, as a 
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validation that the frequency of a given SNP is truly different across the two compared 
groups. 
Whole blood collection and storage 
 
For each patient, 3 mL of whole blood was collected in sodium-heparin tubes. 
Tubes were labeled with a unique anonymous identifier and stored in a −80 °C freezer in 
the St. David’s Medical Center main laboratory. Frozen samples were batch collected 
weekly and transported on dry ice to the Iyer lab at the University of Texas at Austin. 
After transport, sample tubes were stored in a −80 °C freezer until processing. SNP 
analysis of all DNA specimens was conducted simultaneously at the end of the study. 
The researchers at UT Austin responsible for genotyping were blinded about the clinical 
characteristics and identification of the study participants. 
DNA purification protocol 
 
Genomic DNA was isolated from the whole blood using the QIAamp DNA Blood 
Mini kit (51106, Qiagen, Venlo, Netherlands). Heparin was removed from the purified 
genomic DNA using Bacteroides Heparinase I (P0735L, New England Biolabs, Ipswitch, 
MA). Briefly, 24 units of enzyme were added to the genomic DNA and digestion was run 
in a heat block for 2 h at 30 °C. After completion of the digestion, the reaction was 
phenol-chloroform extracted twice using phenol/chloroform/isoamyl alcohol (25:24:1, 
15593-031, Life Technologies, Carlsbad, CA) in phase-lock tubes (2302830 5-Prime, 
Hilden, Germany). The aqueous layer was precipitated in 100 % ethanol at −80 °C for 20 
min, and then centrifuged at 4 °C at maximum speed for 15 min in a refrigerated 
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microfuge. DNA pellets were washed once with 70 % ethanol and centrifuged at 
maximum speed at room temperature for 5 min. Pellets were dried of ethanol for 15 min 
on the bench top and resuspended in 20 μl of diethylpyrocarbonate (DEPC)-treated water 
(AM9906, Life Technologies, Carlsbad, CA). The concentration of each sample was 
quantitated using a NanoDrop ND-1000 (ThermoFisher Scientific, Waltham, MA). These 
concentrations were used to make 50 ng/μl stocks of the genomic DNA in 96-well plates. 
SNP genotyping assays 
 
Genotyping of the samples was performed using a custom made OpenArray 
loaded with TaqMan SNP genotyping assays. The following 16 SNPs were genotyped: 
rs16997168, rs1448817, rs17042171, rs6843082, rs13376333, rs2106261, rs17375901, 
rs3807989, rs11047543, rs7193343, rs3825214, rs7164883, rs251253, rs8192284, 
rs6666258, and rs6599230. To run each OpenArray, 2.5 μl of genomic DNA was added 
to a 384 deep-well plate and mixed with 2.5 μl of TaqMan OpenArray Genotyping 
Master Mix (4404846, Life Technologies, Carlsbad, CA). The 384 deep-well plates were 
then used by the OpenArray AccuFill System (4457243, Life Technologies, Carlsbad, 
CA) to fill each OpenArray plate. Samples were run in triplicate on each plate (48 
individuals per plate) and OpenArrays were filled 2 at a time. After filling and sealing the 
OpenArray, the plates were run using a QuantStudio 12K Flex system (4471090, Life 
Technologies, Carlsbad, CA), utilizing the OpenArray specifications for PCR and plate 
reading after completion of PCR in the DNA Core Facility at UT Austin. After the PCR 
reactions were complete, the fluorescence values for the plate were analyzed using a plate 
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reading utility. This software reads the fluorescence values for each well of the PCR plate 
and determines what alleles are present in each individual for each SNP. 
The raw genotyping data were initially analyzed for consistency across 
individuals and SNP genotypes using TaqMan Genotyper Software (Applied 
Biosystems). While we began our analysis with whole blood samples from 400 
individuals, we removed 29 of those samples from our final analysis for several reasons. 
If we were unable to obtain a consensus genotype after running the SNP assays in 
triplicate two times, we discarded that sample. We also discarded samples that displayed 
very low amplification signals for our assays and samples where the replicates did not 
cluster together after running triplicate experiments twice. We were able to retain 371 of 











Chapter 5: Future directions 
The era of genomics is firmly upon us.  As the cost of high-throughput 
sequencing drops, the amount of sequencing data is increasing at an exponential pace 
[224, 225]. As a whole, the field has noticed this massive influx of data, and the potential 
issues involved in reproducibility of complex experiments, and quality control of 
sequence data [226, 227].  More data is not necessarily better, and care should be taken to 
ensure what questions we ask are feasible to answer with a given experimental design 
[228].  From here, the challenge is to develop tractable, patient relevant, modern models 
of disease, and couple these with best practices in data and experiment reproducibility. 
Chromatin modifiers as drugable targets; Wnt and Hh in cancer 
Bulk GBM tumors contain a signature reminiscent of glioma stem cells that 
suggests Wnt and Hh signaling are important aspects in GBM stemness.  The signatures 
identified in Chapter 2 indicate that Wnt and Hh signaling pathways control enhancer and 
bivalent domains in GBM tumors in a subtype specific manner.  As the Wnt and Hh 
pathways are important therapeutic targets, there are many small molecule inhibitors 
currently in development [229-231].  However, this raises an important question: since 
the main effectors of the Wnt and Hh signaling pathways (WNT1 and SHH, respectively) 
in GBM are bivalent, how can these pathways be targeted pharmacologically?  Clearly 
the repressive H3K27me3 signal must be removed before these genes can be expressed 
(and targeted), so a multi-layered strategy is required.   
First, application of a chromatin modifier (such as the H3K27 demethylases 
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JMJD3 [232] or UTX [233]) to remove the repressive H3K27me3 marks proximal to 
bivalent Wnt and Hh pathway effectors, followed by treatment with Wnt and Hh pathway 
inhibitors to prevent cell proliferation [234]. Chromatin modifiers are altering the 
treatment landscape in GBM, with multiple phase II clinical trials for HDAC inhibitors, 
so a complicated treatment regimen today is not necessarily impossible [235].  This type 
of combination therapy would be complex, and requires extensive preclinical validation 
in a model of GBM that recapitulates essential clinical features to ensure that the drugs 
involved have a robust response in GBM lesions, which are notoriously heterogeneous in 
nature. 
Better in vitro models of disease 
The above example indicates that the biomedical field has outgrown many old in 
vitro model systems.  The era of relying on a small number of immortal and highly 
domesticated cell lines to define genetically complex diseases is drawing to a close.  The 
field requires models that directly reflect essential characteristics of the disease in 
question.  Emerging techniques in genetic engineering and cell culture offer compelling 
paths to this end. Models of stem cells for specific cancers (cancer stem cells, CSCs) are 
becoming more widespread.  Chapter 3 brought up the concept of glioma stem cells 
(GSCs) as a model of the multipotent self-renewing cells present in GBM tumors.  GSCs 
recapitulate the essential characteristics of GBM more effectively than established cell 
line models.  However, improvements in cell culture techniques mean that existing cell 
lines (and the data derived from these lines) can still be useful [236].   
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Improved CSC culture is one aspect of building more relevant models of disease; 
induced pluripotent stem cells (iPSCs) are important paradigm as well. Subtle changes in 
somatic cells over time can result in a cancer, but this takes years.  Taking a skin tissue 
sample from a patient with cancer or a genetic disease allows for an understanding of 
how an individual genetic background influences disease progression or response to 
therapy.  Coupled with organoid culture, tissue-specific drug responses can be measured.  
This has been done to great effect in the intestinal organoids of cystic fibrosis patients 
[237], in cerebellar organoids to model CNS development and microcephaly [238], and in 
patient-derived cardiomyocytes [239]. 
The existence of novel tools doesn’t mean that studying primary tissue is no 
longer necessary, only that it can be recapitulated by using less invasive methods.  
Examining gene expression and chromatin states in primary tissue provides the most 
accurate (if most complex) view of transcriptional regulation across the genome.  Cell 
culture based models should be checked against primary tissue examples to ensure that 
the model matches the phenotype in uncultured material.  Cell culture based models can 
assist in study of primary tissue as well – understanding which cell surface markers 
define tissue-specific stem cells (or other specific populations) can assist in their isolation 
from primary tissue.  Methods such as flow cytometry can assist by purifying specific 
sub-populations of cells from primary tissue for further interrogation [240, 241].  
Coupling flow sorting with chromatin immunoprecipitation and RNA sequencing 
protocols optimized for low numbers of input cells [242, 243] will allow for more 
specific expression, and chromatin based definitions of specific populations of cells from 
 84 
healthy and diseased tissue. 
Noncoding genetic polymorphisms and chromatin topologies  
The above examples deal with gross abnormalities in chromatin structure that 
drastically affect the underlying functionality of the cell(s) and create a clearly neoplastic 
or diseased state.  Most genetic effects are orders of magnitude more subtle than cancer.  
Genetic variation among individuals generally works on a less severe level than 
megabase-scale losses or gains of genetic material [244].  The SNPs genotyped in 
Chapter 4 are subtle, but still cause a small detectable effect in phenotype in some 
subpopulations.  Most human genetic variation works in this manner, and while GWAS 
studies establish genomic regions of interest, they do not put forward a probable model of 
effect.   
Despite these difficult to detect outcomes, studies in chromatin topology are 
revealing potential mechanisms of action [245, 246].  In certain cases, the presence of a 
single nucleotide polymorphism can change a long-range chromosomal interaction [247].  
The use of iPSCs to directly model disease in the genetic background of any specific 
patient is bringing clarity to aspects of disease phenotypes as diverse as macular 
degeneration, spinal muscular atrophy, cystic fibrosis, and cardiovascular disease [239, 
248-250].  Coupling these specific models with directed genome editing using CRISPR-
Cas9 type systems is the first step in targeted gene therapies to prevent disease states 





1. Venter, J.C., et al., The sequence of the human genome. Science, 2001. 
291(5507): p. 1304-51. 
2. Edwards, S.L., et al., Beyond GWASs: illuminating the dark road from 
association to function. Am J Hum Genet, 2013. 93(5): p. 779-97. 
3. Heintzman, N.D., et al., Histone modifications at human enhancers reflect global 
cell-type-specific gene expression. Nature, 2009. 459(7243): p. 108-12. 
4. Consortium, E.P., et al., Identification and analysis of functional elements in 1% 
of the human genome by the ENCODE pilot project. Nature, 2007. 447(7146): p. 
799-816. 
5. Domcke, S., et al., Evaluating cell lines as tumour models by comparison of 
genomic profiles. Nat Commun, 2013. 4: p. 2126. 
6. Vincent, K.M., S.D. Findlay, and L.M. Postovit, Assessing breast cancer cell 
lines as tumour models by comparison of mRNA expression profiles. Breast 
Cancer Res, 2015. 17: p. 114. 
7. Branco, M.R. and A. Pombo, Intermingling of chromosome territories in 
interphase suggests role in translocations and transcription-dependent 
associations. PLoS Biol, 2006. 4(5): p. e138. 
8. Ugarte, F., et al., Progressive Chromatin Condensation and H3K9 Methylation 
Regulate the Differentiation of Embryonic and Hematopoietic Stem Cells. Stem 
Cell Reports, 2015. 5(5): p. 728-40. 
9. Azuara, V., et al., Chromatin signatures of pluripotent cell lines. Nat Cell Biol, 
2006. 8(5): p. 532-8. 
10. Fussner, E., et al., Constitutive heterochromatin reorganization during somatic 
cell reprogramming. EMBO J, 2011. 30(9): p. 1778-89. 
11. Peters, A.H., et al., Loss of the Suv39h histone methyltransferases impairs 
mammalian heterochromatin and genome stability. Cell, 2001. 107(3): p. 323-37. 
12. Barski, A., et al., High-resolution profiling of histone methylations in the human 
genome. Cell, 2007. 129(4): p. 823-37. 
13. Dileep, V., et al., Topologically associating domains and their long-range 
contacts are established during early G1 coincident with the establishment of the 
replication-timing program. Genome Res, 2015. 25(8): p. 1104-13. 
14. Dixon, J.R., et al., Topological domains in mammalian genomes identified by 
analysis of chromatin interactions. Nature, 2012. 485(7398): p. 376-80. 
15. Rao, S.S., et al., A 3D map of the human genome at kilobase resolution reveals 
principles of chromatin looping. Cell, 2014. 159(7): p. 1665-80. 
16. Olins, D.E. and A.L. Olins, Chromatin history: our view from the bridge. Nat Rev 
Mol Cell Biol, 2003. 4(10): p. 809-14. 
17. Zheng, C. and J.J. Hayes, Structures and interactions of the core histone tail 
domains. Biopolymers, 2003. 68(4): p. 539-46. 
 86 
18. Bannister, A.J. and T. Kouzarides, Regulation of chromatin by histone 
modifications. Cell Res, 2011. 21(3): p. 381-95. 
19. Hake, S.B. and C.D. Allis, Histone H3 variants and their potential role in 
indexing mammalian genomes: the "H3 barcode hypothesis". Proc Natl Acad Sci 
U S A, 2006. 103(17): p. 6428-35. 
20. Paull, T.T., et al., A critical role for histone H2AX in recruitment of repair factors 
to nuclear foci after DNA damage. Curr Biol, 2000. 10(15): p. 886-95. 
21. Glaser, S., et al., Multiple epigenetic maintenance factors implicated by the loss of 
Mll2 in mouse development. Development, 2006. 133(8): p. 1423-32. 
22. Denissov, S., et al., Mll2 is required for H3K4 trimethylation on bivalent 
promoters in embryonic stem cells, whereas Mll1 is redundant. Development, 
2014. 141(3): p. 526-37. 
23. Hon, G.C., R.D. Hawkins, and B. Ren, Predictive chromatin signatures in the 
mammalian genome. Hum Mol Genet, 2009. 18(R2): p. R195-201. 
24. Wang, Y., X. Li, and H. Hu, H3K4me2 reliably defines transcription factor 
binding regions in different cells. Genomics, 2014. 103(2-3): p. 222-8. 
25. Pekowska, A., et al., A unique H3K4me2 profile marks tissue-specific gene 
regulation. Genome Res, 2010. 20(11): p. 1493-502. 
26. Lee, J.E., et al., H3K4 mono- and di-methyltransferase MLL4 is required for 
enhancer activation during cell differentiation. Elife, 2013. 2: p. e01503. 
27. Yang, X.J. and E. Seto, HATs and HDACs: from structure, function and 
regulation to novel strategies for therapy and prevention. Oncogene, 2007. 
26(37): p. 5310-8. 
28. Rada-Iglesias, A., et al., A unique chromatin signature uncovers early 
developmental enhancers in humans. Nature, 2011. 470(7333): p. 279-83. 
29. Creyghton, M.P., et al., Histone H3K27ac separates active from poised enhancers 
and predicts developmental state. Proc Natl Acad Sci U S A, 2010. 107(50): p. 
21931-6. 
30. Kratz, A., et al., Core promoter structure and genomic context reflect histone 3 
lysine 9 acetylation patterns. BMC Genomics, 2010. 11: p. 257. 
31. Karmodiya, K., et al., H3K9 and H3K14 acetylation co-occur at many gene 
regulatory elements, while H3K14ac marks a subset of inactive inducible 
promoters in mouse embryonic stem cells. BMC Genomics, 2012. 13: p. 424. 
32. Grant, P.A., et al., Yeast Gcn5 functions in two multisubunit complexes to 
acetylate nucleosomal histones: characterization of an Ada complex and the 
SAGA (Spt/Ada) complex. Genes Dev, 1997. 11(13): p. 1640-50. 
33. Yang, X.J. and E. Seto, The Rpd3/Hda1 family of lysine deacetylases: from 
bacteria and yeast to mice and men. Nat Rev Mol Cell Biol, 2008. 9(3): p. 206-
18. 
34. Fuks, F., et al., The DNA methyltransferases associate with HP1 and the 
SUV39H1 histone methyltransferase. Nucleic Acids Res, 2003. 31(9): p. 2305-12. 
35. Lister, R., et al., Human DNA methylomes at base resolution show widespread 
epigenomic differences. Nature, 2009. 462(7271): p. 315-22. 
 87 
36. Wu, X., J.V. Johansen, and K. Helin, Fbxl10/Kdm2b recruits polycomb repressive 
complex 1 to CpG islands and regulates H2A ubiquitylation. Mol Cell, 2013. 
49(6): p. 1134-46. 
37. Blackledge, N.P., et al., Variant PRC1 complex-dependent H2A ubiquitylation 
drives PRC2 recruitment and polycomb domain formation. Cell, 2014. 157(6): p. 
1445-59. 
38. Chaturvedi, C.P., et al., Maintenance of gene silencing by the coordinate action of 
the H3K9 methyltransferase G9a/KMT1C and the H3K4 demethylase 
Jarid1a/KDM5A. Proc Natl Acad Sci U S A, 2012. 109(46): p. 18845-50. 
39. Shi, L., et al., Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation 
and promotes hormonally responsive breast carcinogenesis. Proc Natl Acad Sci 
U S A, 2011. 108(18): p. 7541-6. 
40. Kim, J.Y., et al., KDM3B is the H3K9 demethylase involved in transcriptional 
activation of lmo2 in leukemia. Mol Cell Biol, 2012. 32(14): p. 2917-33. 
41. Robertson, G., et al., Genome-wide profiles of STAT1 DNA association using 
chromatin immunoprecipitation and massively parallel sequencing. Nat Methods, 
2007. 4(8): p. 651-7. 
42. Park, D., et al., Widespread misinterpretable ChIP-seq bias in yeast. PLoS One, 
2013. 8(12): p. e83506. 
43. Carter, D., et al., Long-range chromatin regulatory interactions in vivo. Nat 
Genet, 2002. 32(4): p. 623-6. 
44. van Berkum, N.L., et al., Hi-C: a method to study the three-dimensional 
architecture of genomes. J Vis Exp, 2010(39). 
45. van de Werken, H.J., et al., 4C technology: protocols and data analysis. Methods 
Enzymol, 2012. 513: p. 89-112. 
46. Ostrom, Q.T., et al., CBTRUS Statistical Report: Primary Brain and Central 
Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro 
Oncol, 2015. 17 Suppl 4: p. iv1-iv62. 
47. Delgado-Lopez, P.D. and E.M. Corrales-Garcia, Survival in glioblastoma: a 
review on the impact of treatment modalities. Clin Transl Oncol, 2016. 18(11): p. 
1062-1071. 
48. Verhaak, R.G., et al., Integrated genomic analysis identifies clinically relevant 
subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, 
EGFR, and NF1. Cancer Cell, 2010. 17(1): p. 98-110. 
49. Nagarajan, R.P., et al., Recurrent epimutations activate gene body promoters in 
primary glioblastoma. Genome Res, 2014. 24(5): p. 761-74. 
50. Lewis, P.W., et al., Inhibition of PRC2 activity by a gain-of-function H3 mutation 
found in pediatric glioblastoma. Science, 2013. 340(6134): p. 857-61. 
51. Chan, K.M., et al., The histone H3.3K27M mutation in pediatric glioma 
reprograms H3K27 methylation and gene expression. Genes Dev, 2013. 27(9): p. 
985-90. 
52. Cenci, T., et al., Prognostic relevance of c-Myc and BMI1 expression in patients 
with glioblastoma. Am J Clin Pathol, 2012. 138(3): p. 390-6. 
 88 
53. Lucio-Eterovic, A.K., et al., Differential expression of 12 histone deacetylase 
(HDAC) genes in astrocytomas and normal brain tissue: class II and IV are 
hypoexpressed in glioblastomas. BMC Cancer, 2008. 8: p. 243. 
54. Lin, C.Y., et al., Active medulloblastoma enhancers reveal subgroup-specific 
cellular origins. Nature, 2016. 530(7588): p. 57-62. 
55. Ernst, J. and M. Kellis, ChromHMM: automating chromatin-state discovery and 
characterization. Nat Methods, 2012. 9(3): p. 215-6. 
56. Sottoriva, A., et al., Intratumor heterogeneity in human glioblastoma reflects 
cancer evolutionary dynamics. Proc Natl Acad Sci U S A, 2013. 110(10): p. 
4009-14. 
57. Harrow, J., et al., GENCODE: the reference human genome annotation for The 
ENCODE Project. Genome Res, 2012. 22(9): p. 1760-74. 
58. Cancer Genome Atlas Research, N., Comprehensive genomic characterization 
defines human glioblastoma genes and core pathways. Nature, 2008. 455(7216): 
p. 1061-8. 
59. Huse, J.T., H.S. Phillips, and C.W. Brennan, Molecular subclassification of 
diffuse gliomas: seeing order in the chaos. Glia, 2011. 59(8): p. 1190-9. 
60. Goodenberger, M.L. and R.B. Jenkins, Genetics of adult glioma. Cancer Genet, 
2012. 205(12): p. 613-21. 
61. Heintzman, N.D., et al., Distinct and predictive chromatin signatures of 
transcriptional promoters and enhancers in the human genome. Nat Genet, 2007. 
39(3): p. 311-8. 
62. Bernstein, B.E., et al., A bivalent chromatin structure marks key developmental 
genes in embryonic stem cells. Cell, 2006. 125(2): p. 315-26. 
63. Lin, B., et al., Global analysis of H3K4me3 and H3K27me3 profiles in 
glioblastoma stem cells and identification of SLC17A7 as a bivalent tumor 
suppressor gene. Oncotarget, 2015. 6(7): p. 5369-81. 
64. Yoo, S. and M.C. Bieda, Differences among brain tumor stem cell types and fetal 
neural stem cells in focal regions of histone modifications and DNA methylation, 
broad regions of modifications, and bivalent promoters. BMC Genomics, 2014. 
15: p. 724. 
65. Stroud, H., et al., 5-Hydroxymethylcytosine is associated with enhancers and gene 
bodies in human embryonic stem cells. Genome Biol, 2011. 12(6): p. R54. 
66. Szulwach, K.E., et al., Integrating 5-hydroxymethylcytosine into the epigenomic 
landscape of human embryonic stem cells. PLoS Genet, 2011. 7(6): p. e1002154. 
67. Johnson, K.C., et al., 5-Hydroxymethylcytosine localizes to enhancer elements 
and is associated with survival in glioblastoma patients. Nat Commun, 2016. 7: p. 
13177. 
68. Wang, H., et al., Widespread plasticity in CTCF occupancy linked to DNA 
methylation. Genome Res, 2012. 22(9): p. 1680-8. 
69. Ashoor, H., et al., DENdb: database of integrated human enhancers. Database 
(Oxford), 2015. 2015. 
 89 
70. Bailey, T.L., et al., The MEME Suite. Nucleic Acids Res, 2015. 43(W1): p. W39-
49. 
71. Huang da, W., B.T. Sherman, and R.A. Lempicki, Systematic and integrative 
analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 
2009. 4(1): p. 44-57. 
72. Szklarczyk, D., et al., STRING v10: protein-protein interaction networks, 
integrated over the tree of life. Nucleic Acids Res, 2015. 43(Database issue): p. 
D447-52. 
73. Lee, I., et al., Prioritizing candidate disease genes by network-based boosting of 
genome-wide association data. Genome Res, 2011. 21(7): p. 1109-21. 
74. Cline, M.S., et al., Integration of biological networks and gene expression data 
using Cytoscape. Nat Protoc, 2007. 2(10): p. 2366-82. 
75. Nakano, I., Stem cell signature in glioblastoma: therapeutic development for a 
moving target. J Neurosurg, 2015. 122(2): p. 324-30. 
76. Cheng, L., et al., Glioblastoma stem cells generate vascular pericytes to support 
vessel function and tumor growth. Cell, 2013. 153(1): p. 139-52. 
77. Kim, S.H., et al., The LIM-only transcription factor LMO2 determines 
tumorigenic and angiogenic traits in glioma stem cells. Cell Death Differ, 2015. 
22(9): p. 1517-25. 
78. Binder, Z.A., et al., Podocalyxin-like protein is expressed in glioblastoma 
multiforme stem-like cells and is associated with poor outcome. PLoS One, 2013. 
8(10): p. e75945. 
79. Kou, Y.B., et al., Knockdown of MMP11 inhibits proliferation and invasion of 
gastric cancer cells. Int J Immunopathol Pharmacol, 2013. 26(2): p. 361-70. 
80. Zhou, W., et al., Up-regulation of S100A16 expression promotes epithelial-
mesenchymal transition via Notch1 pathway in breast cancer. J Biomed Sci, 
2014. 21: p. 97. 
81. Chandran, U.R., et al., Gene expression profiling distinguishes proneural glioma 
stem cells from mesenchymal glioma stem cells. Genom Data, 2015. 5: p. 333-
336. 
82. Warren, A.J., et al., The oncogenic cysteine-rich LIM domain protein rbtn2 is 
essential for erythroid development. Cell, 1994. 78(1): p. 45-57. 
83. Yamada, Y., et al., The oncogenic LIM-only transcription factor Lmo2 regulates 
angiogenesis but not vasculogenesis in mice. Proc Natl Acad Sci U S A, 2000. 
97(1): p. 320-4. 
84. Westcott, J.M., et al., An epigenetically distinct breast cancer cell subpopulation 
promotes collective invasion. J Clin Invest, 2015. 125(5): p. 1927-43. 
85. Zhu, C.Q., et al., Integrin alpha 11 regulates IGF2 expression in fibroblasts to 
enhance tumorigenicity of human non-small-cell lung cancer cells. Proc Natl 
Acad Sci U S A, 2007. 104(28): p. 11754-9. 
86. Mure, H., et al., Akt2 and Akt3 play a pivotal role in malignant gliomas. Neuro 
Oncol, 2010. 12(3): p. 221-32. 
 90 
87. Joy, A., et al., The role of AKT isoforms in glioblastoma: AKT3 delays tumor 
progression. J Neurooncol, 2016. 130(1): p. 43-52. 
88. Patel, V.N., et al., Network signatures of survival in glioblastoma multiforme. 
PLoS Comput Biol, 2013. 9(9): p. e1003237. 
89. Brauer, K., L. Werner, and L. Leibnitz, Perineuronal nets of glia. J Hirnforsch, 
1982. 23(6): p. 701-8. 
90. Chiquet-Ehrismann, R. and R.P. Tucker, Tenascins and the importance of 
adhesion modulation. Cold Spring Harb Perspect Biol, 2011. 3(5). 
91. Hargus, G., et al., Tenascin-R promotes neuronal differentiation of embryonic 
stem cells and recruitment of host-derived neural precursor cells after excitotoxic 
lesion of the mouse striatum. Stem Cells, 2008. 26(8): p. 1973-84. 
92. Wang, Z., et al., MiR-30a-5p is induced by Wnt/beta-catenin pathway and 
promotes glioma cell invasion by repressing NCAM. Biochem Biophys Res 
Commun, 2015. 465(3): p. 374-80. 
93. Jang, C., et al., Calsenilin regulates presenilin 1/gamma-secretase-mediated N-
cadherin epsilon-cleavage and beta-catenin signaling. FASEB J, 2011. 25(12): p. 
4174-83. 
94. Ramis-Conde, I., et al., Multi-scale modelling of cancer cell intravasation: the 
role of cadherins in metastasis. Phys Biol, 2009. 6(1): p. 016008. 
95. Giridharan, S.S., et al., Differential regulation of actin microfilaments by human 
MICAL proteins. J Cell Sci, 2012. 125(Pt 3): p. 614-24. 
96. Mariotti, S., et al., MICAL2 is a novel human cancer gene controlling 
mesenchymal to epithelial transition involved in cancer growth and invasion. 
Oncotarget, 2016. 7(2): p. 1808-25. 
97. Marie, S.K., et al., Stathmin involvement in the maternal embryonic leucine zipper 
kinase pathway in glioblastoma. Proteome Sci, 2016. 14: p. 6. 
98. Wang, R., et al., LRRC4 inhibits the proliferation of human glioma cells by 
modulating the expression of STMN1 and microtubule polymerization. J Cell 
Biochem, 2011. 112(12): p. 3621-9. 
99. Betapudi, V., Myosin II motor proteins with different functions determine the fate 
of lamellipodia extension during cell spreading. PLoS One, 2010. 5(1): p. e8560. 
100. Cai, L., et al., Nonmuscle myosin-dependent synthesis of type I collagen. J Mol 
Biol, 2010. 401(4): p. 564-78. 
101. Thomas, D.G., et al., Non-muscle myosin IIB is critical for nuclear translocation 
during 3D invasion. J Cell Biol, 2015. 210(4): p. 583-94. 
102. Cuddapah, V.A., et al., A neurocentric perspective on glioma invasion. Nat Rev 
Neurosci, 2014. 15(7): p. 455-65. 
103. Liu, Y., et al., Vascular gene expression patterns are conserved in primary and 
metastatic brain tumors. J Neurooncol, 2010. 99(1): p. 13-24. 
104. Rocnik, E.F., et al., The novel SPARC family member SMOC-2 potentiates 
angiogenic growth factor activity. J Biol Chem, 2006. 281(32): p. 22855-64. 
 91 
105. Guezguez, A., et al., Modulation of stemness in a human normal intestinal 
epithelial crypt cell line by activation of the WNT signaling pathway. Exp Cell 
Res, 2014. 322(2): p. 355-64. 
106. Shvab, A., et al., Induction of the intestinal stem cell signature gene SMOC-2 is 
required for L1-mediated colon cancer progression. Oncogene, 2016. 35(5): p. 
549-57. 
107. Ostermann, G., et al., JAM-1 is a ligand of the beta(2) integrin LFA-1 involved in 
transendothelial migration of leukocytes. Nat Immunol, 2002. 3(2): p. 151-8. 
108. Rajaraman, P., et al., Common variation in genes related to innate immunity and 
risk of adult glioma. Cancer Epidemiol Biomarkers Prev, 2009. 18(5): p. 1651-8. 
109. Gao, X., et al., LEF1 regulates glioblastoma cell proliferation, migration, 
invasion, and cancer stem-like cell self-renewal. Tumour Biol, 2014. 35(11): p. 
11505-11. 
110. Rheinbay, E., et al., An aberrant transcription factor network essential for Wnt 
signaling and stem cell maintenance in glioblastoma. Cell Rep, 2013. 3(5): p. 
1567-79. 
111. Liu, B., et al., Overexpressed FOXC2 in ovarian cancer enhances the epithelial-
to-mesenchymal transition and invasion of ovarian cancer cells. Oncol Rep, 
2014. 31(6): p. 2545-54. 
112. Cai, J., et al., FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal 
transition and multidrug resistance of basal-like breast cancer. Cancer Lett, 
2015. 367(2): p. 129-37. 
113. Li, W., et al., FOXC2 often overexpressed in glioblastoma enhances proliferation 
and invasion in glioblastoma cells. Oncol Res, 2013. 21(2): p. 111-20. 
114. Lin, Y., et al., Inorganic phosphate induces cancer cell mediated angiogenesis 
dependent on forkhead box protein C2 (FOXC2) regulated osteopontin 
expression. Mol Carcinog, 2015. 54(9): p. 926-34. 
115. Chen, J., et al., HoxB3 promotes prostate cancer cell progression by 
transactivating CDCA3. Cancer Lett, 2013. 330(2): p. 217-24. 
116. Fu, H., et al., miR-375 inhibits cancer stem cell phenotype and tamoxifen 
resistance by degrading HOXB3 in human ER-positive breast cancer. Oncol Rep, 
2017. 37(2): p. 1093-1099. 
117. Rossi, M., et al., beta-catenin and Gli1 are prognostic markers in glioblastoma. 
Cancer Biol Ther, 2011. 11(8): p. 753-61. 
118. Haupt, Y., et al., Mdm2 promotes the rapid degradation of p53. Nature, 1997. 
387(6630): p. 296-9. 
119. Mizuno, T., et al., Neuronal adhesion molecule telencephalin induces rapid cell 
spreading of microglia. Brain Res, 1999. 849(1-2): p. 58-66. 
120. Tian, L., et al., Binding of T lymphocytes to hippocampal neurons through ICAM-
5 (telencephalin) and characterization of its interaction with the leukocyte 
integrin CD11a/CD18. Eur J Immunol, 2000. 30(3): p. 810-8. 
121. Ashktorab, H., et al., Toward a comprehensive and systematic methylome 
signature in colorectal cancers. Epigenetics, 2013. 8(8): p. 807-15. 
 92 
122. Liu, L., et al., Slit2 and Robo1 expression as biomarkers for assessing prognosis 
in brain glioma patients. Surg Oncol, 2016. 25(4): p. 405-410. 
123. Mi, S., et al., LINGO-1 negatively regulates myelination by oligodendrocytes. Nat 
Neurosci, 2005. 8(6): p. 745-51. 
124. Yin, W. and B. Hu, Knockdown of Lingo1b protein promotes myelination and 
oligodendrocyte differentiation in zebrafish. Exp Neurol, 2014. 251: p. 72-83. 
125. Loov, C., et al., Neutralization of LINGO-1 during in vitro differentiation of 
neural stem cells results in proliferation of immature neurons. PLoS One, 2012. 
7(1): p. e29771. 
126. Zhang, Z., et al., LINGO-1 receptor promotes neuronal apoptosis by inhibiting 
WNK3 kinase activity. J Biol Chem, 2013. 288(17): p. 12152-60. 
127. Ligon, K.L., et al., Olig2-regulated lineage-restricted pathway controls 
replication competence in neural stem cells and malignant glioma. Neuron, 2007. 
53(4): p. 503-17. 
128. Kupp, R., et al., Lineage-Restricted OLIG2-RTK Signaling Governs the 
Molecular Subtype of Glioma Stem-like Cells. Cell Rep, 2016. 16(11): p. 2838-45. 
129. Lu, F., et al., Olig2-Dependent Reciprocal Shift in PDGF and EGF Receptor 
Signaling Regulates Tumor Phenotype and Mitotic Growth in Malignant Glioma. 
Cancer Cell, 2016. 29(5): p. 669-83. 
130. Chen, D., et al., Better prognosis of patients with glioma expressing FGF2-
dependent PDGFRA irrespective of morphological diagnosis. PLoS One, 2013. 
8(4): p. e61556. 
131. Liu, K.W., et al., SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA 
and INK4A/ARF aberrations in mice and humans. J Clin Invest, 2011. 121(3): p. 
905-17. 
132. Todo, T., et al., Expression and growth stimulatory effect of fibroblast growth 
factor 9 in human brain tumors. Neurosurgery, 1998. 43(2): p. 337-46. 
133. Schmid, S., et al., Wnt and hedgehog gene pathway expression in serous ovarian 
cancer. Int J Gynecol Cancer, 2011. 21(6): p. 975-80. 
134. Nicolis, S.K., Cancer stem cells and "stemness" genes in neuro-oncology. 
Neurobiol Dis, 2007. 25(2): p. 217-29. 
135. Feinberg, A.P., M.A. Koldobskiy, and A. Gondor, Epigenetic modulators, 
modifiers and mediators in cancer aetiology and progression. Nat Rev Genet, 
2016. 17(5): p. 284-99. 
136. Murat, A., et al., Stem cell-related "self-renewal" signature and high epidermal 
growth factor receptor expression associated with resistance to concomitant 
chemoradiotherapy in glioblastoma. J Clin Oncol, 2008. 26(18): p. 3015-24. 
137. Tabuse, M., et al., Functional analysis of HOXD9 in human gliomas and glioma 
cancer stem cells. Mol Cancer, 2011. 10: p. 60. 
138. Kurscheid, S., et al., Chromosome 7 gain and DNA hypermethylation at the 
HOXA10 locus are associated with expression of a stem cell related HOX-
signature in glioblastoma. Genome Biol, 2015. 16: p. 16. 
 93 
139. Hu, B., et al., Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell 
Differentiation and Invasive Growth. Cell, 2016. 167(5): p. 1281-1295 e18. 
140. Takebe, N., et al., Targeting Notch, Hedgehog, and Wnt pathways in cancer stem 
cells: clinical update. Nat Rev Clin Oncol, 2015. 12(8): p. 445-64. 
141. Suwala, A.K., et al., Clipping the Wings of Glioblastoma: Modulation of WNT as 
a Novel Therapeutic Strategy. J Neuropathol Exp Neurol, 2016. 75(5): p. 388-96. 
142. Zhang, J., X.J. Tian, and J. Xing, Signal Transduction Pathways of EMT Induced 
by TGF-beta, SHH, and WNT and Their Crosstalks. J Clin Med, 2016. 5(4). 
143. Li, H. and R. Durbin, Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics, 2009. 25(14): p. 1754-60. 
144. Marinov, G.K., et al., Large-scale quality analysis of published ChIP-seq data. 
G3 (Bethesda), 2014. 4(2): p. 209-23. 
145. Zhang, Y., et al., Model-based analysis of ChIP-Seq (MACS). Genome Biol, 
2008. 9(9): p. R137. 
146. Boyle, A.P., et al., High-resolution genome-wide in vivo footprinting of diverse 
transcription factors in human cells. Genome Res, 2011. 21(3): p. 456-64. 
147. Rosenbloom, K.R., et al., The UCSC Genome Browser database: 2015 update. 
Nucleic Acids Res, 2015. 43(Database issue): p. D670-81. 
148. Kent, W.J., et al., The human genome browser at UCSC. Genome Res, 2002. 
12(6): p. 996-1006. 
149. Quinlan, A.R. and I.M. Hall, BEDTools: a flexible suite of utilities for comparing 
genomic features. Bioinformatics, 2010. 26(6): p. 841-2. 
150. Martin, M., Cutadapt removes adapter sequences from high-throughput 
sequencing reads. EMBnet.journal, 2011. 17(1): p. 10-12. 
151. Kim, D., et al., TopHat2: accurate alignment of transcriptomes in the presence of 
insertions, deletions and gene fusions. Genome Biol, 2013. 14(4): p. R36. 
152. Trapnell, C., et al., Differential analysis of gene regulation at transcript 
resolution with RNA-seq. Nat Biotechnol, 2013. 31(1): p. 46-53. 
153. van Staveren, W.C., et al., Human cancer cell lines: Experimental models for 
cancer cells in situ? For cancer stem cells? Biochim Biophys Acta, 2009. 
1795(2): p. 92-103. 
154. Westermark, B., J. Ponten, and R. Hugosson, Determinants for the establishment 
of permanent tissue culture lines from human gliomas. Acta Pathol Microbiol 
Scand A, 1973. 81(6): p. 791-805. 
155. Ponten, J., B. Westermark, and R. Hugosson, Regulation of proliferation and 
movement of human glialike cells in culture. Exp Cell Res, 1969. 58(2): p. 393-
400. 
156. Lee, J., et al., Tumor stem cells derived from glioblastomas cultured in bFGF and 
EGF more closely mirror the phenotype and genotype of primary tumors than do 
serum-cultured cell lines. Cancer Cell, 2006. 9(5): p. 391-403. 
157. Kang, S.K., J.B. Park, and S.H. Cha, Multipotent, dedifferentiated cancer stem-
like cells from brain gliomas. Stem Cells Dev, 2006. 15(3): p. 423-35. 
 94 
158. Mao, P., et al., Mesenchymal glioma stem cells are maintained by activated 
glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci 
U S A, 2013. 110(21): p. 8644-9. 
159. Bhat, K.P., et al., Mesenchymal differentiation mediated by NF-kappaB promotes 
radiation resistance in glioblastoma. Cancer Cell, 2013. 24(3): p. 331-46. 
160. Hossain, A., et al., Mesenchymal Stem Cells Isolated From Human Gliomas 
Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the 
IL-6/gp130/STAT3 Pathway. Stem Cells, 2015. 33(8): p. 2400-15. 
161. Jensen, J.B. and M. Parmar, Strengths and limitations of the neurosphere culture 
system. Mol Neurobiol, 2006. 34(3): p. 153-61. 
162. Azari, H., et al., Isolation and expansion of human glioblastoma multiforme tumor 
cells using the neurosphere assay. J Vis Exp, 2011(56): p. e3633. 
163. Rahman, M., et al., Neurosphere and adherent culture conditions are equivalent 
for malignant glioma stem cell lines. Anat Cell Biol, 2015. 48(1): p. 25-35. 
164. Schnabel, M., et al., Dedifferentiation-associated changes in morphology and 
gene expression in primary human articular chondrocytes in cell culture. 
Osteoarthritis Cartilage, 2002. 10(1): p. 62-70. 
165. Collins, F.S. and L.A. Tabak, Policy: NIH plans to enhance reproducibility. 
Nature, 2014. 505(7485): p. 612-3. 
166. Saraste, M. and M. Hyvonen, Pleckstrin homology domains: a fact file. Curr Opin 
Struct Biol, 1995. 5(3): p. 403-8. 
167. Mayer, B.J., SH3 domains: complexity in moderation. J Cell Sci, 2001. 114(Pt 7): 
p. 1253-63. 
168. Bady, P., et al., DNA fingerprinting of glioma cell lines and considerations on 
similarity measurements. Neuro Oncol, 2012. 14(6): p. 701-11. 
169. Li, D. and R. Roberts, WD-repeat proteins: structure characteristics, biological 
function, and their involvement in human diseases. Cell Mol Life Sci, 2001. 
58(14): p. 2085-97. 
170. Liu, F., et al., EGFR Mutation Promotes Glioblastoma through Epigenome and 
Transcription Factor Network Remodeling. Mol Cell, 2015. 60(2): p. 307-18. 
171. Amessou, M., et al., Spatio-temporal regulation of EGFR signaling by the Eps15 
homology domain-containing protein 3 (EHD3). Oncotarget, 2016. 7(48): p. 
79203-79216. 
172. Dai, X., Z. Liu, and S. Zhang, Over-expression of EPS15 is a favorable 
prognostic factor in breast cancer. Mol Biosyst, 2015. 11(11): p. 2978-85. 
173. Li, M.Y., et al., Protein tyrosine phosphatase PTPN3 inhibits lung cancer cell 
proliferation and migration by promoting EGFR endocytic degradation. 
Oncogene, 2015. 34(29): p. 3791-803. 
174. Han, X., et al., The role of Src family kinases in growth and migration of glioma 
stem cells. Int J Oncol, 2014. 45(1): p. 302-10. 
175. Lu, K.V., et al., Fyn and SRC are effectors of oncogenic epidermal growth factor 
receptor signaling in glioblastoma patients. Cancer Res, 2009. 69(17): p. 6889-
98. 
 95 
176. Zhou, P., et al., CD151-alpha3beta1 integrin complexes are prognostic markers 
of glioblastoma and cooperate with EGFR to drive tumor cell motility and 
invasion. Oncotarget, 2015. 6(30): p. 29675-93. 
177. Aoki, H., et al., Phosphorylated Pak1 level in the cytoplasm correlates with 
shorter survival time in patients with glioblastoma. Clin Cancer Res, 2007. 13(22 
Pt 1): p. 6603-9. 
178. Panicker, S.P., et al., p300- and Myc-mediated regulation of glioblastoma 
multiforme cell differentiation. Oncotarget, 2010. 1(4): p. 289-303. 
179. Alrfaei, B.M., R. Vemuganti, and J.S. Kuo, microRNA-100 targets 
SMRT/NCOR2, reduces proliferation, and improves survival in glioblastoma 
animal models. PLoS One, 2013. 8(11): p. e80865. 
180. van Agthoven, T., et al., CITED2 and NCOR2 in anti-oestrogen resistance and 
progression of breast cancer. Br J Cancer, 2009. 101(11): p. 1824-32. 
181. Dali-Youcef, N., et al., Gene expression mapping of histone deacetylases and co-
factors, and correlation with survival time and 1H-HRMAS metabolomic profile 
in human gliomas. Sci Rep, 2015. 5: p. 9087. 
182. Chen, J., et al., HDAC5 promotes osteosarcoma progression by upregulation of 
Twist 1 expression. Tumour Biol, 2014. 35(2): p. 1383-7. 
183. He, P., et al., HDAC5 promotes colorectal cancer cell proliferation by up-
regulating DLL4 expression. Int J Clin Exp Med, 2015. 8(4): p. 6510-6. 
184. Liu, J., et al., Both HDAC5 and HDAC6 are required for the proliferation and 
metastasis of melanoma cells. J Transl Med, 2016. 14: p. 7. 
185. Li, A., et al., HDAC5, a potential therapeutic target and prognostic biomarker, 
promotes proliferation, invasion and migration in human breast cancer. 
Oncotarget, 2016. 7(25): p. 37966-37978. 
186. Salhia, B., et al., The guanine nucleotide exchange factors trio, Ect2, and Vav3 
mediate the invasive behavior of glioblastoma. Am J Pathol, 2008. 173(6): p. 
1828-38. 
187. Kwiatkowska, A., et al., The small GTPase RhoG mediates glioblastoma cell 
invasion. Mol Cancer, 2012. 11: p. 65. 
188. Gu, F., et al., Intersectin1-S, a multidomain adapter protein, is essential for 
malignant glioma proliferation. Glia, 2015. 63(9): p. 1595-605. 
189. Kitzing, T.M., et al., Positive feedback between Dia1, LARG, and RhoA regulates 
cell morphology and invasion. Genes Dev, 2007. 21(12): p. 1478-83. 
190. Zeng, Y., et al., Formin-like2 regulates Rho/ROCK pathway to promote actin 
assembly and cell invasion of colorectal cancer. Cancer Sci, 2015. 106(10): p. 
1385-93. 
191. Annabi, B., et al., A MT1-MMP/NF-kappaB signaling axis as a checkpoint 
controller of COX-2 expression in CD133+ U87 glioblastoma cells. J 
Neuroinflammation, 2009. 6: p. 8. 
192. Xia, H., et al., Loss of brain-enriched miR-124 microRNA enhances stem-like 
traits and invasiveness of glioma cells. J Biol Chem, 2012. 287(13): p. 9962-71. 
 96 
193. Welter, D., et al., The NHGRI GWAS Catalog, a curated resource of SNP-trait 
associations. Nucleic Acids Res, 2014. 42(Database issue): p. D1001-6. 
194. Bernstein, B.E., et al., The NIH Roadmap Epigenomics Mapping Consortium. Nat 
Biotechnol, 2010. 28(10): p. 1045-8. 
195. Faye, L.L., et al., Re-ranking sequencing variants in the post-GWAS era for 
accurate causal variant identification. PLoS Genet, 2013. 9(8): p. e1003609. 
196. Duggal, G., H. Wang, and C. Kingsford, Higher-order chromatin domains link 
eQTLs with the expression of far-away genes. Nucleic Acids Res, 2014. 42(1): p. 
87-96. 
197. Colilla, S., et al., Estimates of current and future incidence and prevalence of 
atrial fibrillation in the U.S. adult population. Am J Cardiol, 2013. 112(8): p. 
1142-7. 
198. Jais, P., et al., Catheter ablation versus antiarrhythmic drugs for atrial 
fibrillation: the A4 study. Circulation, 2008. 118(24): p. 2498-505. 
199. Mont, L., et al., Catheter ablation vs. antiarrhythmic drug treatment of persistent 
atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). Eur 
Heart J, 2014. 35(8): p. 501-7. 
200. Bhargava, M., et al., Impact of type of atrial fibrillation and repeat catheter 
ablation on long-term freedom from atrial fibrillation: results from a multicenter 
study. Heart Rhythm, 2009. 6(10): p. 1403-12. 
201. Verma, A., et al., Pre-existent left atrial scarring in patients undergoing 
pulmonary vein antrum isolation: an independent predictor of procedural failure. 
J Am Coll Cardiol, 2005. 45(2): p. 285-92. 
202. Di Biase, L., et al., Left atrial appendage: an underrecognized trigger site of 
atrial fibrillation. Circulation, 2010. 122(2): p. 109-18. 
203. Mohanty, S., et al., Impact of metabolic syndrome on procedural outcomes in 
patients with atrial fibrillation undergoing catheter ablation. J Am Coll Cardiol, 
2012. 59(14): p. 1295-301. 
204. Gudbjartsson, D.F., et al., Variants conferring risk of atrial fibrillation on 
chromosome 4q25. Nature, 2007. 448(7151): p. 353-7. 
205. Gudbjartsson, D.F., et al., A sequence variant in ZFHX3 on 16q22 associates with 
atrial fibrillation and ischemic stroke. Nat Genet, 2009. 41(8): p. 876-8. 
206. Benjamin, E.J., et al., Variants in ZFHX3 are associated with atrial fibrillation in 
individuals of European ancestry. Nat Genet, 2009. 41(8): p. 879-81. 
207. Ellinor, P.T., et al., Common variants in KCNN3 are associated with lone atrial 
fibrillation. Nat Genet, 2010. 42(3): p. 240-4. 
208. Ellinor, P.T., et al., Meta-analysis identifies six new susceptibility loci for atrial 
fibrillation. Nat Genet, 2012. 44(6): p. 670-5. 
209. Berry, F.B., et al., Positive and negative regulation of myogenic differentiation of 
C2C12 cells by isoforms of the multiple homeodomain zinc finger transcription 
factor ATBF1. J Biol Chem, 2001. 276(27): p. 25057-65. 
 97 
210. Traylor, M., et al., Genetic risk factors for ischaemic stroke and its subtypes (the 
METASTROKE collaboration): a meta-analysis of genome-wide association 
studies. Lancet Neurol, 2012. 11(11): p. 951-62. 
211. Wang, J., et al., Pitx2-microRNA pathway that delimits sinoatrial node 
development and inhibits predisposition to atrial fibrillation. Proc Natl Acad Sci 
U S A, 2014. 111(25): p. 9181-6. 
212. Wynn, G.J., et al., Efficacy of catheter ablation for persistent atrial fibrillation: a 
systematic review and meta-analysis of evidence from randomized and 
nonrandomized controlled trials. Circ Arrhythm Electrophysiol, 2014. 7(5): p. 
841-52. 
213. Pfeufer, A., et al., Genome-wide association study of PR interval. Nat Genet, 
2010. 42(2): p. 153-9. 
214. Verweij, N., et al., Genetic determinants of P wave duration and PR segment. 
Circ Cardiovasc Genet, 2014. 7(4): p. 475-81. 
215. Sano, M., et al., Genome-wide association study of electrocardiographic 
parameters identifies a new association for PR interval and confirms previously 
reported associations. Hum Mol Genet, 2014. 23(24): p. 6668-76. 
216. Perez-Hernandez, M., et al., Pitx2c increases in atrial myocytes from chronic 
atrial fibrillation patients enhancing IKs and decreasing ICa,L. Cardiovasc Res, 
2016. 109(3): p. 431-41. 
217. Kirchhof, P., et al., PITX2c is expressed in the adult left atrium, and reducing 
Pitx2c expression promotes atrial fibrillation inducibility and complex changes in 
gene expression. Circ Cardiovasc Genet, 2011. 4(2): p. 123-33. 
218. Lozano-Velasco, E., et al., Pitx2 impairs calcium handling in a dose-dependent 
manner by modulating Wnt signalling. Cardiovasc Res, 2016. 109(1): p. 55-66. 
219. Kao, Y.H., et al., ZFHX3 knockdown increases arrhythmogenesis and 
dysregulates calcium homeostasis in HL-1 atrial myocytes. Int J Cardiol, 2016. 
210: p. 85-92. 
220. Jalife, J., Mechanisms of persistent atrial fibrillation. Curr Opin Cardiol, 2014. 
29(1): p. 20-7. 
221. Morgan, R., et al., Slow Conduction in the Border Zones of Patchy Fibrosis 
Stabilizes the Drivers for Atrial Fibrillation: Insights from Multi-Scale Human 
Atrial Modeling. Front Physiol, 2016. 7: p. 474. 
222. Kato, T., et al., Endothelial-mesenchymal transition in human atrial fibrillation. J 
Cardiol, 2017. 69(5): p. 706-711. 
223. Di Biase, L., et al., Periprocedural stroke and bleeding complications in patients 
undergoing catheter ablation of atrial fibrillation with different anticoagulation 
management: results from the Role of Coumadin in Preventing Thromboembolism 
in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) 
randomized trial. Circulation, 2014. 129(25): p. 2638-44. 
224. Wu, Z., Y. Hu, and P.E. Melton, Longitudinal data analysis for genetic studies in 
the whole-genome sequencing era. Genet Epidemiol, 2014. 38 Suppl 1: p. S74-
80. 
 98 
225. Kim, Y.J., et al., A new strategy for enhancing imputation quality of rare variants 
from next-generation sequencing data via combining SNP and exome chip data. 
BMC Genomics, 2015. 16: p. 1109. 
226. Sandve, G.K., et al., Ten simple rules for reproducible computational research. 
PLoS Comput Biol, 2013. 9(10): p. e1003285. 
227. Freedman, L.P. and J. Inglese, The increasing urgency for standards in basic 
biologic research. Cancer Res, 2014. 74(15): p. 4024-9. 
228. Guo, Y., et al., Exome sequencing generates high quality data in non-target 
regions. BMC Genomics, 2012. 13: p. 194. 
229. An, S.M., Q.P. Ding, and L.S. Li, Stem cell signaling as a target for novel drug 
discovery: recent progress in the WNT and Hedgehog pathways. Acta Pharmacol 
Sin, 2013. 34(6): p. 777-83. 
230. Brechbiel, J., K. Miller-Moslin, and A.A. Adjei, Crosstalk between hedgehog and 
other signaling pathways as a basis for combination therapies in cancer. Cancer 
Treat Rev, 2014. 40(6): p. 750-9. 
231. Tai, D., et al., Targeting the WNT Signaling Pathway in Cancer Therapeutics. 
Oncologist, 2015. 20(10): p. 1189-98. 
232. Park, D.H., et al., Activation of neuronal gene expression by the JMJD3 
demethylase is required for postnatal and adult brain neurogenesis. Cell Rep, 
2014. 8(5): p. 1290-9. 
233. Guo, X., et al., Nicotine induces alteration of H3K27 demethylase UTX in kidney 
cancer cell. Hum Exp Toxicol, 2014. 33(3): p. 264-9. 
234. Kahlert, U.D., et al., Pharmacologic Wnt Inhibition Reduces Proliferation, 
Survival, and Clonogenicity of Glioblastoma Cells. J Neuropathol Exp Neurol, 
2015. 74(9): p. 889-900. 
235. Bezecny, P., Histone deacetylase inhibitors in glioblastoma: pre-clinical and 
clinical experience. Med Oncol, 2014. 31(6): p. 985. 
236. Godoy, P.R., A.P. Montaldi, and E.T. Sakamoto-Hojo, HEB silencing induces 
anti-proliferative effects on U87MG cells cultured as neurospheres and 
monolayers. Mol Med Rep, 2016. 14(6): p. 5253-5260. 
237. Schwank, G., et al., Functional repair of CFTR by CRISPR/Cas9 in intestinal 
stem cell organoids of cystic fibrosis patients. Cell Stem Cell, 2013. 13(6): p. 653-
8. 
238. Lancaster, M.A., et al., Cerebral organoids model human brain development and 
microcephaly. Nature, 2013. 501(7467): p. 373-9. 
239. Egashira, T., et al., Patient-Specific Induced Pluripotent Stem Cell Models: 
Characterization of iPS Cell-Derived Cardiomyocytes. Methods Mol Biol, 2016. 
1353: p. 343-53. 
240. Chang, Q. and D. Hedley, Emerging applications of flow cytometry in solid tumor 
biology. Methods, 2012. 57(3): p. 359-67. 
241. Denes, V., et al., Metastasis blood test by flow cytometry: in vivo cancer 
spheroids and the role of hypoxia. Int J Cancer, 2015. 136(7): p. 1528-36. 
 99 
242. Gilfillan, G.D., et al., Limitations and possibilities of low cell number ChIP-seq. 
BMC Genomics, 2012. 13: p. 645. 
243. Saliba, A.E., et al., Single-cell RNA-seq: advances and future challenges. Nucleic 
Acids Res, 2014. 42(14): p. 8845-60. 
244. Sulem, P., et al., Identification of a large set of rare complete human knockouts. 
Nat Genet, 2015. 47(5): p. 448-52. 
245. Cai, M., et al., 4C-seq revealed long-range interactions of a functional enhancer 
at the 8q24 prostate cancer risk locus. Sci Rep, 2016. 6: p. 22462. 
246. Meddens, C.A., et al., Systematic analysis of chromatin interactions at disease 
associated loci links novel candidate genes to inflammatory bowel disease. 
Genome Biol, 2016. 17(1): p. 247. 
247. Wang, S., et al., An enhancer element harboring variants associated with systemic 
lupus erythematosus engages the TNFAIP3 promoter to influence A20 expression. 
PLoS Genet, 2013. 9(9): p. e1003750. 
248. Wiley, L.A., et al., Patient-specific induced pluripotent stem cells (iPSCs) for the 
study and treatment of retinal degenerative diseases. Prog Retin Eye Res, 2015. 
44: p. 15-35. 
249. Yoshida, M., et al., Modeling the early phenotype at the neuromuscular junction 
of spinal muscular atrophy using patient-derived iPSCs. Stem Cell Reports, 2015. 
4(4): p. 561-8. 
250. Novak, A., et al., Functional abnormalities in iPSC-derived cardiomyocytes 
generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin 
mutations. J Cell Mol Med, 2015. 19(8): p. 2006-18. 
251. Xie, F., et al., Seamless gene correction of beta-thalassemia mutations in patient-
specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res, 2014. 24(9): p. 
1526-33. 
252. Li, H.L., et al., Precise correction of the dystrophin gene in duchenne muscular 
dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. 
Stem Cell Reports, 2015. 4(1): p. 143-54. 
253. Huang, X., et al., Production of Gene-Corrected Adult Beta Globin Protein in 
Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of 
















Amelia Weber Hall was born in Austin, TX, December 1984.  After a childhood 
in New England spent transplanting large hods of moss from one rock to another rock, 
she enrolled at the University of Rochester in August 2003.  There, in the “Flour City”, 
she spent 4 years studying science, religion, living in an ecologically minded vegetarian 
commune, and dating a burly ginger math enthusiast. In May of 2006 she got her start as 
a molecular biologist-for-hire in the laboratory of Dr. Vera Gorbunova and graduated 
with BS in Molecular Genetics (Distinction in Research) in May of 2007.  
In August of 2007, Amelia and her burly ginger set out for Austin, Texas. This 
was 6 to 12 months before Austin officially became the destination for “cool 
millennials”, and they unwittingly set off a trend.  From August 2007 until May 2010 
Amelia worked as a laboratory technician for Dr. Richard Aldrich at UT Austin, and 
learned how to be slightly less socially awkward through the power of friendship.  In 
August of 2010, she began graduate school at the University of Texas at Austin and 
joined the laboratory of Dr. Vishy Iyer in May of 2011. 
 
Permanent email:  ameliahall [at] utexas [dot] edu 
This dissertation was typed by Amelia Weber Hall. 
 
